%PDF-1.3
%
2 0 obj
<>
endobj
3 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
24 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
20 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
9 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
6 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
12 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
14 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
4 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
18 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
8 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
7 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
28 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
27 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
13 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
25 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
5 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
17 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
15 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
21 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
10 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
1 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
19 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
11 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
23 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
22 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
16 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
26 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
29 0 obj
<>stream
Acrobat Distiller 8.1.0 (Windows); modified using iText 4.2.0 by 1T3XT
Arbortext Advanced Print Publisher 9.0.114/W
2014-11-11T00:28:45-08:00
2014-10-23T14:08:23+05:30
application/pdf
untitled
uuid:222d0496-f370-4762-ba63-736fae3d6051
uuid:8ac109fc-6e53-4a8f-8464-7e0509a58304
endstream
endobj
30 0 obj
<>stream
x+ |
endstream
endobj
31 0 obj
<>stream
xS**T0T0 BiU !D. _e1
endstream
endobj
32 0 obj
<>stream
x+ |
endstream
endobj
33 0 obj
<>stream
xS**T0T0 BiUD* :
endstream
endobj
34 0 obj
<>stream
x+ |
endstream
endobj
35 0 obj
<>stream
xS**T0T0 BiU)D* 9V
endstream
endobj
36 0 obj
<>stream
x+ |
endstream
endobj
37 0 obj
<>stream
xS**T0T0 Bid]D. qdj
endstream
endobj
38 0 obj
<>stream
x+ |
endstream
endobj
39 0 obj
<>stream
xS**T0T0 Bid]1D. pa
endstream
endobj
40 0 obj
<>stream
x+ |
endstream
endobj
41 0 obj
<>stream
xS**T0T0 BiUD* 8
endstream
endobj
42 0 obj
<>stream
x+ |
endstream
endobj
43 0 obj
<>stream
xS**T0T0 Bih] D. pa
endstream
endobj
44 0 obj
<>stream
x+ |
endstream
endobj
45 0 obj
<>stream
xS**T0T0 Bih]D. r^j
endstream
endobj
46 0 obj
<>stream
x+ |
endstream
endobj
47 0 obj
<>stream
xS**T0T0 Bih]9D. qaj
endstream
endobj
48 0 obj
<>/XObject<>/ProcSet [/PDF /Text /ImageB /ImageC /ImageI]/Font<>>>/Thumb 61 0 R/MediaBox[0 0 612 792]/Rotate 0>>
endobj
62 0 obj
<>/ProcSet[/PDF/Text]/Font<>>>
endobj
50 0 obj
<>stream
/GS1 gs
BT
/F4 1 Tf
9.843 0 0 9.843 62.022 725.5557 Tm
0 0 0 rg
0 Tc
0 Tw
[(nonconstant)-239.1(drug)-240.5(dosage)-239.1(therapy)-240.5(to)-238.5(control)-239.5(the)-240.7(virus)-241.6(dynam-)]TJ
0 -1.1174 TD
[(ics)-303.9(and)-298.2(to)-301.8(minimize)-302(undesired)-305.9(side)-299.2(effects.)]TJ
7.3823 0 0 6.5614 233.1779 718.9794 Tm
(911)Tj
9.843 0 0 9.843 72 703.6156 Tm
[(Following)-212.6(t)16.1(h)21.9(i)21.8(s)-196.7(l)21.8(i)21.8(n)21.9(e)-198.1(o)21.9(f)-191.1(i)16.1(n)21.9(t)21.8(e)20.8(r)16.2(d)21.9(i)21.8(s)16.4(c)20.8(i)21.8(p)16.2(l)21.8(i)21.8(n)16.2(a)20.8(r)22(y)-196.9(r)22(e)20.8(s)16.4(e)20.8(a)20.8(r)16.2(c)20.8(h)21.9(,)-193.5(t)21.8(h)16.2(e)-192.3(a)20.8(c)20.8(h)16.2(i)21.8(e)20.8(v)21.9(e)15(-)]TJ
-1.0137 -1.1116 TD
-.0204 Tc
[(me)-5.4(nts)-303.5(t)1.4(ha)-5.4(t)-298.1(t)1.4(his)-297.8(r)-4.2(eview)-298.8(a)-5.4(rticle)-304.9(emphasizes)-303.5(are)-304.9(a).4(s)-297.8(f)-4.2(ollows:)]TJ
1.0022 -1.7222 TD
0 Tc
[(1.)-499.9(A)-226.6(clinical)-237.4(trial)-231.7(has)-228.9(been)-231.4(set)-234.8(up)-226.8(for)-233.6(the)-229.2(rst)-234.5(time)-231.7(to)-227(show)]TJ
1.2499 -1.1116 TD
[(that)-218.9(mathematical)-223.6(systems)-217(analysis)-224.1(is)-215.2(useful)-220.8(to)-215.4(help)-218.8(cli-)]TJ
0 -1.1174 TD
[(nicians)-229(in)-227(an)-228(early)-226.8(diagnosis)-229.8(and)-229.1(in)-227(taking)-226.9(decisions)-231(for)]TJ
0 -1.1116 TD
[(treating)-299.5(HIV-in)-8.4(fected)-298.2(patients,)]TJ
-1.2499 -1.1116 TD
[(2.)-499.9(An)-590.6(optimal)-592.2(\(time-varying\))-595.2(dosage)-590.5(is)-589.6(generated)-596.4(by)]TJ
1.2499 -1.1116 TD
[(taking)-388.2(into)-384.8(account)-385.7(the)-384.7(desired)-390.1(dynamics)-386.7(for)-389.1(the)-384.7(im-)]TJ
0 -1.1174 TD
[(mune)-358.1(system)-354.3(as)-360.3(well)-358(as)-360.3(the)-355.9(side)-356.8(effects)-362.4(generated)-360.2(by)]TJ
0 -1.1116 TD
[(antiretroviral)-503.3(drugs)-494.9(after)-497.5(initiation)-502.5(of)-491.7(the)-499.9(treatment.)]TJ
T*
[(This)-276.2(is)-272.8(one)-280.9(of)-272.9(the)-275.3(perspectives)-282.7(offered)-280.6(by)-272.9(a)-278.7(mathemat-)]TJ
0 -1.1174 TD
[(ical)-300.7(approach.)]TJ
-1.2499 -1.1116 TD
[(3.)-499.9(The)-552.8(control)-550.5(action)-556.4(\(therapy\))-553.7(is)-555.1(computed)-553.9(in)-549.5(terms)]TJ
1.2499 -1.1116 TD
[(of)-336.2(the)-332.9(drug)-338.4(dosage)-337(in)-336.4(milligrams,)-340.9(which)-336(is)-336.2(signicant)]TJ
0 -1.1174 TD
[(for)-729(real-life)-733.7(practitione)-10.3(rs,)-731.1(whereas)-731.8(earlier)-737.1(articles)]TJ
0 -1.1116 TD
[(consider)-402.7(the)-396.3(efciency)-406.2(of)-393.8(drugs)-402.7(as)-394.8(the)-402(control)-400.8(input.)]TJ
T*
[(Pharmacokinetic)-582.5(and)-574.7(pharmacodynamic)-577.8(models)-579.1(are)]TJ
0 -1.1174 TD
[(included)-299.4(in)-301.8(the)-304.1(HIV)-298.8(model.)]TJ
-1.2383 -1.918 TD
[(The)-305.2(outline)-303(of)-301.7(this)-304(review)-309.4(is)-301.6(as)-302.7(follows.)-305.8(The)-305.2(next)-305.2(section)]TJ
-1.0137 -1.1174 TD
[(introduces)-364.7(a)-365.1(model)-359.4(of)-365(the)-361.7(infection)-363.9(dynamics.)-367.1(The)-362.8(clinical)]TJ
0 -1.1116 TD
[(research)-376.1(results)-377.3(are)-374.2(then)-374.3(described,)-379.6(including)-374.3(the)-373.2(methods,)]TJ
T*
[(and)-609.2(a)-607(discussion)-610.9(of)-606.9(the)-603.6(results.)-611.2(Namely,)-607.9(the)-609.4(identied)]TJ
0 -1.1174 TD
[(model)-232.7(is)-232.5(argued)-233.5(to)-232.7(be)-228(an)-233.7(efcient)-237(tool)-229.3(for)-233.6(characterizing)-235.8(crit-)]TJ
0 -1.1116 TD
[(ical)-260.4(patients)-264.8(and)-257.9(for)-262.4(the)-258(diagnosis)-264.4(of)-261.4(clinical)-260.5(failure)-263.7(within)-261.3(1)]TJ
T*
[(month)-404.3(after)-411.1(initiation)-410.4(of)-405.3(a)-405.4(new)-408.5(therapy.)-411(More)-403.9(prospective)]TJ
0 -1.1174 TD
[(research)-278.1(is)-267.1(reviewed,)-275.9(and)-269.4(strategies)-273.7(for)-273.9(the)-269.5(control)-268.3(of)-272.9(the)-269.5(in-)]TJ
0 -1.1116 TD
[(fection)-350.1(dynamics)-346.4(using)-351(drug)-344.2(treatments)-350(are)-351.2(revisited)-346.5(in)-347.9(the)]TJ
T*
[(framework)-354.1(of)-347.7(engineering)-355.7(and)-344.3(computational)-353.6(methods.)-353.3(For)]TJ
T*
[(these)-422.5(prospective)-424.6(strategies,)-426.8(only)]TJ
/F8 1 Tf
14.1919 0 TD
[(in)-422.8(silico)]TJ
/F4 1 Tf
3.8014 0 TD
[(results)-423.4(are)-420.3(pre-)]TJ
-17.9933 -1.1174 TD
[(sented)-446.6(because)-444.1(no)-445.7(clinical)-444.8(study)-443.2(is)-445.6(available)-446.9(yet.)-440(Finally,)]TJ
0 -1.1116 TD
[(conclusions)-302.3(are)-305.1(presented.)]TJ
/F1 1 Tf
8.9663 0 0 8.9663 62.022 338.0031 Tm
[(Basic)-304.1(Modeling)-301.3(of)-298.6(the)-303(Infection)-302.6(Dynamics)]TJ
/F4 1 Tf
9.843 0 0 9.843 72 321.5621 Tm
[(Several)-224.2(nonlinear)-219.8(models)-222(have)-219.8(been)-225.6(developed)-220.9(to)-221.2(describe)]TJ
-1.0137 -1.1116 TD
[(the)-390.5(dynamics)-386.7(of)-388.1(the)-390.5(HIV-1)-393.1(virus,)-383.2(which)-393.6(take)-387(into)-390.6(account)]TJ
0 -1.1174 TD
[(the)-309.9(kinetics)-310.8(of)-307.4(the)-309.9(HIV)-310.3(infection)-306.3(with)-310.8(different)-311.9(cell)-306.5(popula-)]TJ
0 -1.1116 TD
[(tions;)-329.3(for)-325.8(exam)-8(ple,)-324.8(macrophages,)-332.2(cytotoxic)-335.2(T)-324.8(lymphocytes,)]TJ
T*
[(latently)-253.6(infected)-254.4(CD4)]TJ
/F7 1 Tf
7.3823 0 0 6.5614 148.3653 282.1038 Tm
(+)Tj
/F4 1 Tf
9.843 0 0 9.843 156.1322 277.7385 Tm
[(T)-250(cells)-249.8(as)-250.8(well)-248.6(as)-250.8(the)-252.3(lymphoid)-252.2(com-)]TJ
-9.5611 -1.1174 TD
(partments.)Tj
7.3823 0 0 6.5614 103.4645 271.1054 Tm
(12,13)Tj
9.843 0 0 9.843 72 255.7984 Tm
[(With)-375.5(a)-388.2(g)-6.9(o)-12.6(a)-8(l)-387.1(o)-6.9(f)-387(p)-12.6(r)-6.8(o)-12.6(v)-6.9(i)-12.7(d)-12.6(i)-7(n)-12.6(g)-381.2(u)-12.6(s)-12.4(e)-8(f)-12.6(u)-6.9(l)-387.1(d)-12.6(i)-7(a)-13.8(g)-6.9(n)-12.6(o)-12.6(s)-6.7(t)-12.7(i)-7(c)-388.2(i)-12.7(n)-6.9(f)-12.6(o)-6.9(r)-12.6(m)-8.1(a)-13.8(t)-12.7(i)-7(o)-12.6(n)]TJ
-1.0137 -1.1116 TD
.0121 Tc
[(an)5.2(d)-651.4(c)4.1(ont)5.1(ro)5.2(lli)5.1(ng)-645.6(the)-646.8(i)-.6(n)5.2(f)-.5(ecti)5.1(on)5.2(,)-653.7(t)5.1(he)-646.8(main)-651.4(charact)5.1(e)-1.7(ri)5.1(sti)5.1(c)-1.7(s)]TJ
0 -1.1174 TD
.0115 Tc
[(of)-277.5(th)4.6(e)-284.5(H)-2(I)4.7(V)-284.2(d)4.6(ynami)4.5(cs)-277.4(can)-283.3(b)-1.1(e)-278.7(m)-2.3(o)4.6(d)-1.1(eled)-283.3(based)-283.3(o)4.6(n)-283.3(a)-284.5(r)4.7(e)-2.3(l)4.5(a)-2.3(ti)4.5(vely)]TJ
0 -1.1116 TD
.0124 Tc
[(si)5.4(mp)5.5(le)-421.8(s)5.7(e)-1.4(t)-420.8(o)5.5(f)-420.6(o)-.2(r)5.6(d)-.2(in)5.5(ar)5.6(y)-420.7(d)-.2(i)5.4(fferenti)5.4(a)-1.4(l)-420.8(e)4.4(qu)5.5(at)5.4(ion)5.5(s)0(.)-417.2(I)-.2(n)-420.7(f)5.6(act,)-417.2(the)]TJ
T*
.013 Tc
[(si)6(mp)6.1(le)5(st)-299.2(mo)6.1(de)5(l)-299.2(o).4(f)-299.1(t).3(h)6.1(e)-300.3(HI)6.2(V/A)5.3(I).4(D)5.3(S)-299(dyn)6.1(am)4.9(ic)5(s)-298.9(\().4(w)5.3(h).4(ic)5(h)-299.1(i).3(s)-298.9(u).4(s)6.3(e)-.8(d)]TJ
0 -1.1174 TD
.0126 Tc
[(herein\))-616.3(c)4.6(an)-616.3(b)5.7(e)-617.5(und)5.7(er)5.8(sto)5.7(o)0(d)-616.3(t)5.6(hro)5.7(ug)5.7(h)-616.3(t)-.1(he)-617.5(i)5.6(n)0(t)5.6(e)-1.2(r)5.8(act)5.6(io)5.7(ns)-616.1(of)]TJ
0 -1.1116 TD
.0111 Tc
[(heal)4.1(thy)-491.1(C)-2.5(D4)]TJ
/F7 1 Tf
7.3823 0 0 6.5614 116.844 194.3999 Tm
0 Tc
(+)Tj
/F4 1 Tf
9.843 0 0 9.843 127.1055 190.0346 Tm
.012 Tc
[(cells)-490(\()]TJ
/F8 1 Tf
2.7359 0 TD
0 Tc
(T)Tj
/F4 1 Tf
.5645 0 TD
.0133 Tc
[(\))6.5(,)-497(i)6.3(nfe)5.3(ct)6.3(ed)-488.9(CD4)]TJ
/F7 1 Tf
7.3823 0 0 6.5614 228.0755 194.3999 Tm
0 Tc
(+)Tj
/F4 1 Tf
9.843 0 0 9.843 238.3936 190.0346 Tm
.0089 Tc
[(ce)-4.9(lls)-498.9(\()]TJ
/F8 1 Tf
2.7301 0 TD
0 Tc
(T)Tj
/F4 1 Tf
.5645 0 TD
.0126 Tc
[(*\))5.8(,)-497.7(a)4.6(nd)]TJ
-21.213 -1.1116 TD
.0122 Tc
[(fr)5.4(ee)-301.1(v)5.3(i)-.5(r)5.4(u)-.4(ses)-299.7(\()]TJ
/F8 1 Tf
5.4544 0 TD
0 Tc
(V)Tj
/F4 1 Tf
.622 0 TD
(\))Tj
7.3823 0 0 6.5614 125.2346 183.4582 Tm
(3)Tj
9.843 0 0 9.843 129.033 179.0929 Tm
(:)Tj
/F9 1 Tf
-.8179 -1.6934 TD
(_)Tj
/F8 1 Tf
-.1843 -.2131 TD
(T)Tj
/F7 1 Tf
.8006 0 TD
(=)Tj
/F8 1 Tf
.72 0 TD
(s)Tj
/F10 1 Tf
.5529 0 TD
()Tj
/F11 1 Tf
.9331 0 TD
(d)Tj
/F8 1 Tf
.5011 0 TD
(T)Tj
/F10 1 Tf
.8006 0 TD
()Tj
/F4 1 Tf
.9388 0 TD
(\(1)Tj
/F10 1 Tf
1.0022 0 TD
()Tj
/F11 1 Tf
.9388 0 TD
(g)Tj
/F4 1 Tf
6.8899 0 0 6.8899 196.4409 158.0031 Tm
(1)Tj
9.843 0 0 9.843 200.4094 160.3275 Tm
(\))Tj
/F11 1 Tf
.3341 0 TD
(b)Tj
/F8 1 Tf
.5529 0 TD
(TV)Tj
/F10 1 Tf
1.4111 0 TD
()Tj
/F8 1 Tf
.9388 0 TD
(ATT)Tj
/F10 1 Tf
6.8899 0 0 6.8899 250.0157 164.3527 Tm
()Tj
/F4 1 Tf
9.843 0 0 9.843 289.644 160.3275 Tm
(\(1\))Tj
/F9 1 Tf
-15.4706 -2.4191 TD
(_)Tj
/F8 1 Tf
-.1843 -.2131 TD
(T)Tj
/F7 1 Tf
.8006 0 TD
(=)Tj
/F4 1 Tf
.72 0 TD
(\(1)Tj
/F10 1 Tf
1.0022 0 TD
()Tj
/F11 1 Tf
.9331 0 TD
(g)Tj
/F4 1 Tf
6.8899 0 0 6.8899 176.1448 132.1511 Tm
(1)Tj
9.843 0 0 9.843 180.1133 134.4189 Tm
(\))Tj
/F11 1 Tf
.3341 0 TD
(b)Tj
/F8 1 Tf
.5472 0 TD
(TV)Tj
/F10 1 Tf
1.4169 0 TD
()Tj
/F11 1 Tf
.9388 0 TD
(l)Tj
/F8 1 Tf
.5529 0 TD
(T)Tj
/F10 1 Tf
6.8899 0 0 6.8899 223.6535 138.5007 Tm
()Tj
/F4 1 Tf
9.843 0 0 9.843 289.644 134.4189 Tm
(\(2\))Tj
/F9 1 Tf
-15.0904 -2.4133 TD
(_)Tj
/F8 1 Tf
-.2131 -.2131 TD
(V)Tj
/F7 1 Tf
.864 0 TD
(=)Tj
/F4 1 Tf
.7142 0 TD
(\(1)Tj
/F10 1 Tf
1.0022 0 TD
()Tj
/F11 1 Tf
.9388 0 TD
(g)Tj
/F4 1 Tf
6.8899 0 0 6.8899 180.2267 106.2425 Tm
(2)Tj
9.843 0 0 9.843 184.1385 108.5669 Tm
(\))Tj
/F8 1 Tf
.3341 0 TD
(kT)Tj
/F10 1 Tf
6.8899 0 0 6.8899 198.085 112.6488 Tm
()Tj
9.843 0 0 9.843 203.6409 108.5669 Tm
()Tj
/F8 1 Tf
.9388 0 TD
(cV)Tj
/F4 1 Tf
7.7986 0 TD
(\(3\))Tj
-23.1252 -1.8373 TD
[(where)-244.8(healthy)-246.4(CD4)]TJ
/F7 1 Tf
7.3823 0 0 6.5614 139.8047 94.8472 Tm
(+)Tj
/F4 1 Tf
9.843 0 0 9.843 147.5149 90.4819 Tm
[(cells)-249.8(\()]TJ
/F8 1 Tf
2.4191 0 TD
(T)Tj
/F4 1 Tf
.5529 0 TD
[(\))-243(are)-247.5(produced)-247.3(from)-241.7(the)-246.5(thymus)]TJ
-11.6576 -1.1116 TD
[(at)-222.4(a)-215.4(constant)-224.3(rate)]TJ
/F8 1 Tf
6.9059 0 TD
(s)Tj
/F4 1 Tf
.6048 0 TD
[(and)-223.3(die)-217.7(with)-218.6(a)-221.1(half-life)-225.6(time)-220.2(equal)-221.1(to)]TJ
ET
280.176 81.808 3.4016 .39685 re
f
BT
6.8899 0 0 6.8899 280.1763 83.1118 Tm
(1)Tj
/F11 1 Tf
0 -1.0039 TD
(d)Tj
/F4 1 Tf
9.843 0 0 9.843 285.7322 79.5401 Tm
(The)Tj
-22.7278 -1.1116 TD
[(healthy)-246.4(cells)-249.8(are)-241.7(infected)-248.7(by)-244.1(the)-246.5(virus)-241.6(at)-245.4(a)-244.2(rate)-248.7(that)-247.7(is)-244(propor-)]TJ
0 -1.1174 TD
[(tional)-273.1(to)-273(the)-269.5(product)-273.9(of)-267.1(their)-277.6(population)-271.8(size)-271.6(and)-269.4(the)-275.3(amount)]TJ
25.504 67.8609 TD
[(of)-353.5(free)-352.2(virus)-351(particles.)-351.1(The)-351.2(proportionality)-352.3(constant)]TJ
/F12 1 Tf
21.4261 0 TD
(b)Tj
/F4 1 Tf
.9043 0 TD
[(is)-347.7(an)]TJ
-22.3304 -1.1174 TD
[(indication)-589.8(of)-583.9(the)-580.6(effectiveness)-590.2(of)-583.9(the)-586.3(infection)-582.8(process.)]TJ
0 -1.1116 TD
[(The)-334(term)]TJ
/F8 1 Tf
4.0664 0 TD
(ATT*)Tj
/F4 1 Tf
2.5515 0 TD
[(is)-330.4(included)-328.2(to)-330.6(take)-329.4(into)-333(account)-333.9(that,)-331.8(in)-324.9(the)]TJ
-6.6179 -1.1116 TD
[(presence)-289.7(of)-284.4(infected)-283.2(cells)-290.1(\()]TJ
/F8 1 Tf
10.8916 0 TD
(T)Tj
/F4 1 Tf
.5529 0 TD
[(*\),)-282.1(healthy)-286.8(CD4)]TJ
/F7 1 Tf
7.3823 0 0 6.5614 490.8471 697.0392 Tm
(+)Tj
/F4 1 Tf
9.843 0 0 9.843 498.9542 692.6738 Tm
[(cells)-284.4(undergo)]TJ
-18.8861 -1.1116 TD
[(activation-)-10.3(induced)-298.1(apoptosis.)]TJ
7.3823 0 0 6.5614 429.3353 686.0974 Tm
(7,14)Tj
9.843 0 0 9.843 323.0361 670.7337 Tm
[(The)-535.6(infected)-536.7(CD4)]TJ
/F7 1 Tf
7.3823 0 0 6.5614 400.592 675.0991 Tm
(+)Tj
/F4 1 Tf
9.843 0 0 9.843 411.1936 670.7337 Tm
[(cells)-537.8(result)-531.9(from)-535.5(the)-534.5(infection)-536.7(of)]TJ
-9.9701 -1.1116 TD
[(healthy)-390.4(CD4)-391.1(cells)-388(and)-384.6(die)-390.5(at)-383.6(a)-388.2(rate)]TJ
/F12 1 Tf
15.1423 0 TD
(l)Tj
/F4 1 Tf
.5529 0 TD
[(.)-389.3(Free)-386.7(virus)-385.6(particles)]TJ
-15.6952 -1.1116 TD
[(are)-426.1(produced)-420.1(from)-420.3(infected)-421.5(CD4)-419.9(cells)-422.6(at)-418.2(a)-417(rate)]TJ
/F8 1 Tf
20.3318 0 TD
(k)Tj
/F4 1 Tf
.864 0 TD
[(and)-419.2(die)]TJ
-21.1957 -1.1174 TD
[(with)-230.2(a)-221.1(half-life)-231.4(time)-225.9(equal)-226.8(to)]TJ
ET
1 i
q 1 0 0 1 426.898 640.516 cm 0 0 m
3.458 0 l
3.458 -.397 l
0 -.397 l
f*
Q
BT
6.8899 0 0 6.8899 426.8975 641.4235 Tm
(1)Tj
/F8 1 Tf
.0247 -1.0039 TD
(c)Tj
/F4 1 Tf
9.843 0 0 9.843 430.3558 637.8518 Tm
[(.)-222.3(The)-224.5(parameters)]TJ
/F12 1 Tf
6.8886 0 TD
(g)Tj
/F4 1 Tf
7.3823 0 0 6.5614 503.0928 636.2077 Tm
(1)Tj
9.843 0 0 9.843 508.9889 637.8518 Tm
(and)Tj
/F12 1 Tf
1.6761 0 TD
(g)Tj
/F4 1 Tf
7.3823 0 0 6.5614 530.4188 636.2077 Tm
(2)Tj
9.843 0 0 9.843 536.3148 637.8518 Tm
(rep-)Tj
-22.6817 -1.1116 TD
[(resent)-268(the)-263.8(efcacy)-265.6(of)-267.1(an)-262.5(anti-HIV)-265.3(treatment,)-266.1(which)-266.9(is)-261.3(gener-)]TJ
T*
[(ally)-409(a)-405.4(cocktail)-404.4(of)-405.3(drugs)-402.7(composed)-403.8(of)-405.3(reverse)-408.4(transcriptase)]TJ
0 -1.1174 TD
[(inhibitors)-362.7(and)-355.8(protease)-363.5(inhibitors.)-360.3(Reverse)-363.4(transcriptase)-358.7(in-)]TJ
0 -1.1116 TD
[(hibitors)-492.8(are)-483.6(usually)-487(considered)-492.5(to)-486.1(affect)-488.2(the)-488.4(parameter)]TJ
/F12 1 Tf
23.7415 0 TD
(b)Tj
/F4 1 Tf
-23.7415 -1.1116 TD
[(and)-327(protease)-329(inhibitors,)-325.8(the)-321.4(parameter)]TJ
/F8 1 Tf
15.7586 0 TD
(k)Tj
/F4 1 Tf
.4435 0 TD
(.)Tj
7.3823 0 0 6.5614 475.0298 587.4518 Tm
(3,15,16)Tj
9.843 0 0 9.843 500.3715 583.0865 Tm
[(In)-324.7(particular,)]TJ
/F12 1 Tf
-19.0301 -1.1174 TD
(g)Tj
/F4 1 Tf
7.3823 0 0 6.5614 317.9904 570.5006 Tm
(1)Tj
/F7 1 Tf
9.843 0 0 9.843 323.3196 572.088 Tm
(=)Tj
/F12 1 Tf
.72 0 TD
(g)Tj
/F4 1 Tf
7.3823 0 0 6.5614 335.3385 570.5006 Tm
(2)Tj
/F7 1 Tf
9.843 0 0 9.843 340.6676 572.088 Tm
(=)Tj
/F4 1 Tf
.72 0 TD
[(0)-231.5(represents)-238.8(a)-232.6(null)-229.3(therapy,)-232.4(while)]TJ
/F12 1 Tf
13.4547 0 TD
(g)Tj
/F4 1 Tf
7.3823 0 0 6.5614 485.0645 570.5006 Tm
(1)Tj
/F7 1 Tf
9.843 0 0 9.843 490.4503 572.088 Tm
(=)Tj
/F12 1 Tf
.7142 0 TD
(g)Tj
/F4 1 Tf
7.3823 0 0 6.5614 502.4125 570.5006 Tm
(2)Tj
/F7 1 Tf
9.843 0 0 9.843 507.7416 572.088 Tm
(=)Tj
/F4 1 Tf
.72 0 TD
[(1)-231.5(denotes)]TJ
-20.4988 -1.1116 TD
.0124 Tc
[(a)-421.8(100)5.5(%)-421.7(e)-1.4(f)5.6(f)-.2(ecti)5.4(ve)-421.8(t)5.4(h)-.2(erap)5.5(y.)-417.2(Eq)5.5(uat)5.4(i)-.3(o)5.5(n)-420.7(3)-420.7(t)-.3(ak)5.5(es)-420.5(i)5.4(n)-.2(to)-420.7(accou)5.5(n)-.2(t)]TJ
T*
.0116 Tc
[(the)-376.6(f)4.8(act)-375.5(t)-1.1(hat)-375.5(o)-1(n)4.7(e)-376.6(vir)4.8(u)-1(s)-375.2(p)-1(art)4.6(i)-1.1(cle)-376.6(c)-2.2(an)-375.4(on)4.7(ly)-375.4(in)4.7(fect)-375.5(on)4.7(e)-376.6(s)-.8(i)4.6(ngl)4.6(e)]TJ
T*
.0136 Tc
(CD4)Tj
/F7 1 Tf
7.3823 0 0 6.5614 333.1842 543.6282 Tm
0 Tc
(+)Tj
/F4 1 Tf
9.843 0 0 9.843 340.044 539.2628 Tm
.0133 Tc
[(ce)5.3(ll)6.3(.)]TJ
/F1 1 Tf
8.9663 0 0 8.9663 313.0582 516.6991 Tm
0 Tc
[(Clinical)-303.3(Research:)-305.3(EDV05)-298.3(Clinical)-303.3(Trial)-302.4(Design)]TJ
0 -1.2203 TD
[(and)-306.6(Early)-295.5(Diagnosis)-305.6(of)-298.6(Therapeutic)-305.9(Failure)]TJ
/F4 1 Tf
9.843 0 0 9.843 323.0361 489.3164 Tm
[(Among)-549(a)-549.4(general)-547(population)-548.2(of)-549.3(HIV-infected)-548.5(patients)]TJ
-1.0137 -1.1116 TD
[(starting)-286.6(a)-284.5(new)-281.8(therapy,)-284.3(some)-283.1(individuals)-284.3(will)-282.1(eventually)-279.8(un-)]TJ
T*
[(dergo)-237(a)-232.6(so-called)-238.1(immunological)-232.7(failure.)-238.3(One)-230(main)-231.6(contribu-)]TJ
0 -1.1174 TD
[(tion)-258.1(reviewed)-255.2(here)-254.4(is)-249.8(to)-255.8(show)-252.7(that)-253.5(parameter)-257.8(identication)-254.5(is)]TJ
0 -1.1116 TD
[(able)-214.2(to)-209.7(predict)-217.6(such)-207(failures)-218.5(after)-209.5(1)-214.2(month)-208.5(from)-212.9(the)-211.9(beginning)]TJ
T*
[(of)-445.7(the)-448.1(treatment,)-450.4(while)-445.5(the)-442.3(immunolog)-6.9(ical)-444.7(failure)-448(usually)]TJ
0 -1.1174 TD
[(takes)-399.4(6)-398.5(months)-393.7(to)-399.7(be)-395(diagnosed)-398.1(during)-398.4(a)-393.9(standard)-396.9(clinical)]TJ
0 -1.1116 TD
(monitoring.)Tj
1.0137 -1.1116 TD
[(As)-371.5(previously)-375.1(stated,)-375.3(immunological)-371(failure)-373.1(is)-376.5(clinically)]TJ
-1.0137 -1.1174 TD
[(declared)-434(when)-426.9(the)-430.8(amount)-429.6(of)-422.6(CD4)-431.4(T)-428.5(cells)-428.3(remains)-431.6(under)]TJ
0 -1.1116 TD
[(200)-314.3(CD4/mm)]TJ
7.3823 0 0 6.5614 367.6534 384.0944 Tm
(3)Tj
9.843 0 0 9.843 374.3999 379.729 Tm
[(during)-317.7(6)-312.1(months)-313(of)-313.2(efcient)-317.6(treatment.)]TJ
7.3823 0 0 6.5614 529.9652 384.0944 Tm
[(5,1)-9.4(7,18)]TJ
9.843 0 0 9.843 313.0582 368.7873 Tm
[(A)-318.7(treatment)-320.3(is)-313.2(dened)-319.8(as)-314.2(efcient,)-321.1(if)-313.3(it)-319.2(yields)-313.1(a)-319(decrease)-319.7(of)]TJ
0 -1.1174 TD
[(the)-373.2(viral)-369.8(load)-368.6(below)-370.5(the)-373.2(detectable)-374.3(threshold)-374(of)-365(50)-370.8(copies/)]TJ
0 -1.1116 TD
[(mL)-304.1(and)-298.2(keeps)-307.1(the)-298.3(viral)-300.6(load)-305.2(below)-301.4(this)-298.2(limit)-306.8(afterwards.)]TJ
1.0137 -1.1116 TD
[(A)-203.6(central)-213(paradox)-205.8(for)-204.8(HIV)-206.6(patients)-207.2(who)-205.8(are)-207.2(in)-203.9(immunolog-)]TJ
-1.0137 -1.1116 TD
[(ical)-248.9(failure)-252.1(is)-244(that)-247.7(their)-248.8(viral)-248.8(load)-247.6(seems)-250.6(too)-245.3(low)-246.2(to)-244.2(be)-245.3(able)-248.8(to)]TJ
0 -1.1174 TD
[(deple)-8(te)-297.2(the)-298.3(CD4)]TJ
/F7 1 Tf
7.3823 0 0 6.5614 379.4456 318.3306 Tm
(+)Tj
/F4 1 Tf
9.843 0 0 9.843 387.7227 313.9653 Tm
[(population)-300.6(by)-295.9(direct)-302.9(killing)-302(alone.)-299.4(In)-301.7(this)]TJ
-7.5855 -1.1116 TD
[(respect,)-388.9(the)-390.5(rst)-384.3(studies)]TJ
7.3823 0 0 6.5614 409.6629 307.3889 Tm
(8)Tj
9.843 0 0 9.843 417.1463 303.0235 Tm
[(relate)-390.5(immunological)-388.3(failure)-390.4(to)-382.5(a)]TJ
-10.5748 -1.1116 TD
[(dysfunctional)-212.7(thymus,)-207(which)-209.3(is)-209.5(unable)-210.7(to)-203.9(produce)-211.6(a)-203.8(sufcient)]TJ
0 -1.1174 TD
[(amount)-262.6(of)-261.4(healthy)-263.7(CD4)]TJ
/F7 1 Tf
7.3823 0 0 6.5614 407.5085 285.4487 Tm
(+)Tj
/F4 1 Tf
9.843 0 0 9.843 415.3889 281.0834 Tm
[(T)-261.5(cells.)-264.8(However,)-262.9(a)-261.4(different)-265.8(point)]TJ
-10.3963 -1.1116 TD
[(of)-249.8(view)-248.5(is)-249.8(argued)-250.8(in)-244.2(the)-252.3(section)-252(Prospective)-251.6(Research:)-251.7(Infec-)]TJ
T*
[(tion)-252.3(Control)-256.6(and)-252.1(Drug)-252.9(Dosage,)-255(which)-249.6(relates)-258.9(immunological)]TJ
0 -1.1174 TD
[(failur)-8(e)-198.1(t)0(o)-203.9(a)0(n)-199.2(important)-202.7(activation-induced)-210.6(apoptosis)-201(phenom-)]TJ
0 -1.1116 TD
[(enon)-212.9(in)-209.7(the)-211.9(transient)-214(stage)-209.4(of)-209.5(the)-211.9(infection.)-211.9(This)-207.1(point)-213.1(of)-209.5(view)]TJ
T*
[(is)-382.3(supported)-385.4(by)-382.3(several)-385.5(research)-387.6(articles,)]TJ
7.3823 0 0 6.5614 479.1117 230.6834 Tm
[(7,14,192)-8.7(4)]TJ
9.843 0 0 9.843 516.1321 226.3181 Tm
[(based)-382(on)]TJ
-20.6313 -1.1116 TD
[(thymic)-256.9(function)-252.1(having)-249.8(little)-250.3(chance)-253.2(to)-250(vary)-253.2(within)-249.8(a)-249.9(healthy)]TJ
0 -1.1174 TD
[(adult)-254.6(population.)-252.2(Whether)-260.1(immunological)-255.8(failure)-252.1(is)-249.8(predom-)]TJ
0 -1.1116 TD
[(inantly)-360.6(due)-355.8(to)-353.7(a)-359.4(badly)-352.4(damaged)-358(thymus)-359.1(or)-353.5(to)-353.7(an)-360.5(important)]TJ
T*
[(activation-)-10.3(induced)-355.7(apoptosis)-356.5(phenomenon)-360.2(remains)-356.8(an)-360.5(open)]TJ
0 -1.1174 TD
[(questi)-7.8(on.)]TJ
/F13 1 Tf
8.9663 0 0 8.9663 313.0582 150.0661 Tm
(Methods)Tj
/F4 1 Tf
9.843 0 0 9.843 323.0361 133.6818 Tm
[(To)-262.6(generate)-267(useful)-261.1(data)-266(for)-262.4(the)-258(chara)-9(cterization)-264.9(of)-261.4(the)-263.8(im-)]TJ
-1.0137 -1.1174 TD
[(munologica)-9.1(l)-410.2(failures,)-412(the)-413.5(EDV05)-411.6(trial)-416(was)-414.1(initiated)-416.1(at)-406.7(the)]TJ
0 -1.1116 TD
[(University)-283.9(Hospital)-281.8(of)-278.6(Nantes)-286.2(in)-278.8(February)-281.6(2005,)-278.5(and)-280.9(six)-279.7(pa-)]TJ
T*
[(tients)-267.2(were)-266.8(included)-264.8(in)-261.5(the)-263.8(rst)-263.3(part)-264.9(of)-261.4(this)-263.7(trial.)-263.9(In)-261.4(2007)-263.6(and)]TJ
0 -1.1174 TD
[(2008,)-330.4(10)-324.7(other)-329.3(patients)-328.1(were)-330.1(enrolled.)-331.6(The)-328.2(main)-323.7(conditions)]TJ
0 -1.1116 TD
[(for)-325.8(each)-318.9(patient)-321.5(\(female)-329.3(or)-319(male\))-320.2(to)-319.1(be)-320.1(included)-322.4(in)-324.9(the)-321.4(trial)]TJ
T*
[(were)-209.2(as)-204.8(follows:)-205.7(aged)-208.3(over)-207.1(18)-203.8(years)-203.4(old,)-208.5(having)-203.7(been)-202.6(infected)]TJ
0 -1.1174 TD
[(by)-388.1(the)-384.7(HIV-1)-387.3(or)-382.3(HIV-2)-387.3(type)-385.8(virus,)-383.2(having)-388(no)-382.3(co-infection)]TJ
/F1 1 Tf
8.9663 0 0 8.9663 62.022 749.5368 Tm
(234)Tj
44.2983 0 TD
[(RIVADENEIRA)-308.5(ET)-300.7(AL.)]TJ
ET
endstream
endobj
63 0 obj
<>/XObject<>/ProcSet [/PDF /Text /ImageB /ImageC /ImageI]/Font<>/Properties<>>>/Thumb 72 0 R/MediaBox[0 0 612 792]/Rotate 0>>
endobj
73 0 obj
<>/ProcSet[/PDF/Text]/Font<>/Properties<>>>
endobj
64 0 obj
<>stream
/GS1 gs
BT
/F4 1 Tf
9.843 0 0 9.843 59.7543 725.5557 Tm
0 0 0 rg
0 Tc
0 Tw
[(with)-241.7(hepatitis)-243(B)-238.3(o)0(r)-238.3(hepatitis)-243(C)-238.3(virus)-241.6(during)-237.1(the)-240.7(6)-237.2(months)-243.9(pre-)]TJ
0 -1.1174 TD
[(ceding)-377.7(their)-375.5(inclus)-7.8(ion)-372.1(in)-376.7(the)-373.2(trial,)-379.1(starting)-378.8(an)-372(antiretroviral)]TJ
0 -1.1116 TD
[(treatment)-308.7(at)-303(the)-304.1(beginning)-305.1(of)-301.7(the)-304.1(trial,)-298.4(and)-304(not)-302.9(showing)-302.3(any)]TJ
T*
[(resistance)-309.2(to)-301.8(the)-298.3(treatment)-303(that)-305.3(will)-299.4(be)-302.9(administrated.)]TJ
1.0137 -1.1116 TD
[(The)-305.2(measured)-307.1(data)-306.4(consisted)-305.9(of)-307.4(the)-304.1(viral)-306.4(load)-305.2(and)-304(the)-304.1(to-)]TJ
-1.0137 -1.1174 TD
[(tal)-442.5(CD4)-442.9(T)-440(cells.)-443.3(Eleven)-448(samples)-443(were)-445.3(collected)-441.2(during)-444.4(3)]TJ
0 -1.1116 TD
[(months,)-472(but)-475.7(the)-471.1(relevant)-473.3(information)-475.6(about)-473.3(the)-471.1(dynamics)]TJ
T*
[(\(six)-378.7(or)-376.5(seven)-376.3(blood)-380(samples\))-380.7(was)-373.8(taken)-382.3(within)-376.5(the)-373.2(rst)-378.5(20)]TJ
0 -1.1174 TD
[(days.)-302.6(This)-293.5(specic)-304.7(sampling)-299.3(protocol)-298.2(enables)-299.1(a)-296(rst)-297.9(estima-)]TJ
0 -1.1116 TD
[(tion)-281.1(of)-284.4(all)-281.2(the)-281.1(parameters)-281.7(of)-284.4(the)-281.1(mathematical)-287(model)-278.7(\(Equa-)]TJ
T*
[(tions)-247.5(13)-239.4(with)]TJ
/F12 1 Tf
5.9555 0 TD
(g)Tj
/F4 1 Tf
7.3823 0 0 6.5614 123.307 614.3242 Tm
(1)Tj
/F7 1 Tf
9.843 0 0 9.843 128.6362 615.9683 Tm
(=)Tj
/F4 1 Tf
.72 0 TD
(0\).)Tj
7.3823 0 0 6.5614 146.3811 620.3337 Tm
(4,8)Tj
9.843 0 0 9.843 158.0031 615.9683 Tm
[(From)-247.3(day)-240.6(30)-244.1(to)-238.5(day)-246.4(90,)-241.8(only)-240.7(four)-240.5(or)]TJ
-9.9816 -1.1174 TD
[(ve)-240.5(other)-237.2(samples)-241.4(were)-238(taken,)-236(with)-241.7(a)-232.6(sampl)-7.8(ing)-233.8(time)-237.4(of)-238.3(about)]TJ
0 -1.1116 TD
[(15)-267.1(days.)-268(Since)-267(the)-263.8(measured)-266.7(viral)-266.1(load)-264.9(values)-268.1(depend)-268.1(on)-261.4(the)]TJ
T*
[(laboratory)-278.5(protocol)-269.4(used)-276.1(to)-273(quantify)-269.4(the)-275.3(RNA)-271(copies,)]TJ
7.3823 0 0 6.5614 271.1621 587.4518 Tm
(16,2528)Tj
9.843 0 0 9.843 59.7543 572.088 Tm
[(it)-342.3(was)-339.2(decided)-339.6(for)-337.3(each)-342(patient)-338.7(to)-336.4(perform)-338.3(all)-338.8(the)-338.7(measure-)]TJ
T*
[(ments)-249.7(of)-244.1(the)-240.7(viral)-248.8(load)-241.8(at)-245.4(the)-246.5(same)-249.7(time)-243.2(with)-247.4(the)-240.7(same)-249.7(proto-)]TJ
T*
[(col.)-267.2(Thus,)-262.3(the)-258(11)-261.4(blood)-264.8(samples)-264.4(from)-264.7(each)-261.3(patient)-263.9(were)-266.8(kept)]TJ
T*
[(frozen)-291.1(\(at)]TJ
/F10 1 Tf
4.2046 0 TD
()Tj
/F4 1 Tf
.766 0 TD
(80)Tj
/F7 1 Tf
1.0022 0 TD
()Tj
/F4 1 Tf
.3974 0 TD
[(C\))-285.4(until)-288.1(the)-292.6(end)-286.7(of)-284.4(the)-292.6(trial)-289.2(\(see)-288.7(Fig.)-288.9(1\).)-287.8(The)]TJ
-6.3702 -1.1174 TD
[(measurements)-331.1(were)-318.6(done)-322.4(at)-326(the)-321.4(same)-318.8(time)-323.8(using)-322.2(the)-321.4(Roche)]TJ
0 -1.1116 TD
[(Taqman)-403(48)]TJ
7.3823 0 0 6.5614 105.9023 521.688 Tm
(TM)Tj
9.843 0 0 9.843 120.9259 517.3227 Tm
[(test,)-400.7(with)-397.2(a)-393.9(detectable)-403.1(threshold)-397(of)-399.6(50)-393.9(cop-)]TJ
-6.2147 -1.1116 TD
[(ies/mL)-240.6(\(CD4)-230.9(T)-232.7(cells)-238.3(and)-234.8(virus)-230(load)-236.1(values)-233.5(for)-233.6(the)-235(16)-232.6(patients)]TJ
0 -1.1174 TD
[(are)-305.1(given)-300.5(in)-301.8(table)-301.8(2)-300.6(o)0(f)-301.7(Prudhomme)-302.4(et)-303(al.)]TJ
7.3823 0 0 6.5614 225.8645 499.7479 Tm
(29)Tj
9.843 0 0 9.843 233.2346 495.3825 Tm
(\).)Tj
-16.611 -1.1116 TD
[(Based)-296.7(on)-295.9(clinical)-295(observations,)-301(Mhawej)-298.8(et)-291.5(al.)]TJ
7.3823 0 0 6.5614 251.6598 488.8062 Tm
(4)Tj
9.843 0 0 9.843 258.2928 484.4408 Tm
(concluded)Tj
-20.1705 -1.1116 TD
[(that)-501.2(th)20.7(e)-486.1(i)0(d)20.7(e)0(n)13.9(t)0(i)20.6()0(c)19.8(a)0(t)19.5(i)0(o)20.7(n)-484.9(of)-480.2(th)20.7(e)-486.1(p)0(a)19.7(r)0(a)19.7(m)0(e)18.4(t)0(e)19.6(r)0(s)-480(o)0(f)-474.5(t)0(h)15(e)-486.1(dy)20.8(na)19.7(mi)19.5(ca)18.5(l)]TJ
0 -1.1174 TD
[(mo)19.6(de)19.7(l)-283.5(\()0(E)19.7(q)0(u)20.8(a)0(t)19.5(i)0(o)20.7(n)0(s)-266.9(1)0()20.8(3)-277.6(wi)14.1(th)]TJ
/F12 1 Tf
11.0702 0 TD
(g)Tj
/F4 1 Tf
7.3823 0 0 6.5614 173.537 460.8566 Tm
(1)Tj
/F7 1 Tf
9.843 0 0 9.843 178.7527 462.5007 Tm
(=)Tj
/F4 1 Tf
.7084 0 TD
[(0\))-272.9(al)19.5(lo)20.7(ws)-267.8(de)19.7(n)21(in)20.7(g)-277.6(a)-284.5(qu)20.8(an)19.7(ti)20.6(-)]TJ
-12.7981 -1.1116 TD
[(ab)19.7(le)-205.1(im)19.5(m)15(u)0(n)15.1(o)0(l)20.7(o)0(g)20.8(i)0(c)19.6(a)0(l)-199.3(s)0(t)20.9(a)0(t)13.8(u)0(s)21(.)-205(Si)15.1(nc)19.7(e)-209.6(a)0(v)19.7(a)0(i)19.5(l)0(a)19.6(b)0(l)20.7(e)-209.6(me)18.4(as)19.9(ur)15.1(em)24.2(en)13.9(ts)-198(ty)20.7(p-)]TJ
T*
[(ic)19.6(al)13.8(ly)-273(co)19.7(nt)20.7(ai)19.5(n)-289.1(t)0(h)20.7(e)-284.5(to)20.7(ta)19.5(l)-289.2(\()0(u)20.9(n)0(i)20.7(n)0(f)20.9(e)0(c)18.5(t)0(e)19.6(d)-289.1(an)19.7(d)-283.3(i)0(n)20.7(f)0(e)14(c)0(t)19.5(e)0(d)19.7(\))-283.3(CD)18.9(4)-289.1(T)-284.5(ce)18.5(ll)20.6(s)]TJ
0 -1.1174 TD
[(an)19.7(d)-375.5(f)0(r)15.1(e)0(e)-361.6(v)0(i)20.7(r)0(i)15(o)0(n)20.8(s)0(,)-361.4(t)0(h)15(e)-370.9(pa)19.7(ra)14(m)15(e)0(t)13.8(e)0(r)19.7(s)-375.3(of)-365(th)20.7(e)-376.6(p)0(r)20.9(o)0(p)20.8(o)0(s)21(e)0(d)-366.2(m)0(o)19.6(d)0(e)19.7(l)-375.6(ca)18.5(n)]TJ
0 -1.1116 TD
[(on)15.1(ly)-347.9(be)-354.7(de)19.7(te)19.6(rm)19.6(in)20.7(ed)-348.9(fr)15.1(om)-349(th)20.7(es)19.9(e)-365.1(o)0(u)20.8(t)0(p)20.7(u)0(t)-353.7(m)15(ea)12.8(su)21(re)19.7(me)18.4(nt)20.7(s)-363.8(\()0(b)20.9(l)0(o)20.7(o)0(d)]TJ
T*
[(sa)14.1(m)15(p)0(l)14.9(e)0(s)19.9(\))-289(un)20.8(de)19.7(r)-289(c)0(e)12.8(r)0(t)20.7(a)0(i)19.5(n)-289.1(id)20.7(en)19.7(ti)20.6(a)14.1(bi)20.7(li)20.6(ty)-278.8(co)19.7(nd)20.8(it)14.8(io)20.7(ns)21(.)]TJ
7.3823 0 0 6.5614 248.5417 412.1007 Tm
-.0162 Tc
(30)Tj
9.843 0 0 9.843 69.7323 396.7936 Tm
0 Tc
[(The)-247.6(identication)-242.9(method)-245.3(used)-247.3(in)-244.2(this)-240.6(reviewed)-249.4(study)-241.6(was)]TJ
-1.0137 -1.1174 TD
[(developed)-209.4(by)-209.5(Ouattara)]TJ
7.3823 0 0 6.5614 148.3086 390.1605 Tm
(5)Tj
9.843 0 0 9.843 154.0346 385.7952 Tm
[(and)-206.1(Ouattara)-209.2(et)-205.1(al.)]TJ
7.3823 0 0 6.5614 225.1842 390.1605 Tm
(8)Tj
9.843 0 0 9.843 230.9102 385.7952 Tm
[(and)-206.1(implemented)]TJ
-17.3886 -1.1116 TD
[(in)-267.3(software)-265.3(available)-268.4(in)-261.5(reference)-274.8(6.)-258(The)-270.6(method)-262.6(is)-261.3(based)-266.8(on)]TJ
T*
[(the)-384.7(Monte)-376.3(Carlo)-382.2(approach,)-384.3(combined)-381.1(with)-379.9(a)-376.6(simplex)-378.8(opti-)]TJ
0 -1.1174 TD
[(mization)-542.7(method.)-536.7(To)-533.3(avoid)-536.7(local)-538(optima,)-536.8(random)-538.9(initial)]TJ
0 -1.1116 TD
[(conditions)-277.3(were)-278.3(drawn)-272.5(from)-276.3(uniform)-273.9(distributions)-279.5(in)-273(the)-269.5(ad-)]TJ
T*
[(missible)-310.7(parameter)-309.6(space)-308.3(and)-304(corresponding)-310.3(estimates)-314.1(were)]TJ
0 -1.1174 TD
[(computed.)-361.5(Using)-357.7(the)-355.9(median)-361.6(and)-355.8(interquartile)-364(range)-359.1(of)-353.5(the)]TJ
0 -1.1116 TD
[(estimates)-321(distributions,)-317.5(reliable)-317.9(estimations)-321.1(and)-309.7(condence)]TJ
T*
[(intervals)-306.1(of)-307.4(the)-304.1(parameters)-310.5(were)-301.3(deduced.)-308.4(For)-302.6(Equations)-306.1(1)]TJ
25.5097 43.4224 TD
[(3)-294.8(\(with)]TJ
/F12 1 Tf
3.2024 0 TD
(g)Tj
/F4 1 Tf
7.3823 0 0 6.5614 347.3007 723.9116 Tm
(1)Tj
/F7 1 Tf
9.843 0 0 9.843 352.6298 725.5557 Tm
(=)Tj
/F4 1 Tf
.72 0 TD
[(0\),)-293.6(a)-290.2(number)-297(of)-295.9(1000)-292.4(randomizations)-296.8(was)-298.9(suf-)]TJ
-4.9649 -1.1174 TD
[(cient)-313.4(to)-313.3(obtain)-313.3(stable)-314.3(and)-315.5(robust)-311.8(results.)]TJ
7.3823 0 0 6.5614 471.0613 718.9794 Tm
(8)Tj
9.843 0 0 9.843 477.8644 714.5573 Tm
[(The)-310.9(calibration)-315.6(of)]TJ
-16.9681 -1.1116 TD
[(the)-298.3(algorithm)-306.4(was)-298.9(as)-302.7(follows:)]TJ
/F10 1 Tf
.9964 -1.7222 TD
()Tj
/F4 1 Tf
1.0022 0 TD
[(Life-time)-239.6(parameters)-235.6(were)-238(set)-234.8(to)-232.7(constant)-235.8(values,)-236.9(which)]TJ
0 -1.1116 TD
[(relied)-435.4(on)-434.2(typical)-442.4(values)-435.1(published)-437.4(in)-434.3(Ouattara)-439.6(et)-435.5(al.)]TJ
7.3823 0 0 6.5614 546.2361 680.088 Tm
(8)Tj
9.843 0 0 9.843 330.5196 664.7809 Tm
[(These)-302.6(were)]TJ
/F12 1 Tf
4.9476 0 TD
(d)Tj
/F7 1 Tf
.6624 0 TD
(=)Tj
/F4 1 Tf
.72 0 TD
(0.01/d,)Tj
/F12 1 Tf
3.0814 0 TD
(l)Tj
/F7 1 Tf
.72 0 TD
(=)Tj
/F4 1 Tf
.72 0 TD
[(0.05/d,)-300.5(and)]TJ
/F8 1 Tf
4.8266 0 TD
(c)Tj
/F7 1 Tf
.6163 0 TD
(=)Tj
/F4 1 Tf
.72 0 TD
(0.3/d.)Tj
/F10 1 Tf
-18.0164 -1.1174 TD
()Tj
/F4 1 Tf
1.0022 0 TD
[(According)-393.4(t)16.1(o)-335.2(t)16.1(h)16.2(e)-336.3(b)16.2(i)16(o)16.2(lo)26.5(g)16.2(i)16.1(c)15(a)15(l)-335.3(c)15(h)16.2(ar)25.5(a)15(c)15(t)16(e)15(r)0(i)26.5(s)16.4(t)16.1(i)0(c)25.3(s)-329.2(of)-318.9(th)26.5(e)-330.6(i)0(n)26.5(f)16.2(e)15(c)15(-)]TJ
0 -1.1116 TD
-.0158 Tc
[(tio)-15.8(n)10.8(,)-220.8(t).3(he)-219.6(o)-15.8(t)10.7(her)-218.5(p)-15.8(a)9.6(r).4(amet)-15.8(e)9.5(r).4(s)-218.3(w)-15.8(e)8.8(r).4(e)-219.6(c)-.8(o)-15.8(n)10.8(stra)-15.8(i)9.5(n).4(ed)-218.5(t)-15.8(o)-208.2(be)-219.6(b)-15.8(o)10.8(unded)]TJ
T*
-.0159 Tc
[(in)-593(the)-588.4(f).3(o)-15.9(l)10.6(lowi)-15.9(n)10.6(g)-587.2(int)-15.9(e)9.4(rvals)-15.9(:)]TJ
/F8 1 Tf
11.6346 0 TD
0 Tc
(s)Tj
/F10 1 Tf
.6624 0 TD
(2)Tj
/F4 1 Tf
.9331 0 TD
([1)Tj
/F8 1 Tf
.8352 0 TD
(E)Tj
/F10 1 Tf
.8006 0 TD
()Tj
/F4 1 Tf
.9388 0 TD
[(5,)-165.8(2)16.2(0],)]TJ
/F12 1 Tf
2.6495 0 TD
(b)Tj
/F10 1 Tf
.6624 0 TD
(2)Tj
/F4 1 Tf
.7718 0 TD
([1)Tj
/F8 1 Tf
.8294 0 TD
(E)Tj
/F10 1 Tf
.8006 0 TD
()Tj
/F4 1 Tf
-21.5183 -1.1116 TD
[(2)16.2(0)0(,)-165.8(1],)]TJ
/F8 1 Tf
2.6495 0 TD
(A)Tj
/F10 1 Tf
.7257 0 TD
(2)Tj
/F4 1 Tf
.7718 0 TD
([1)Tj
/F8 1 Tf
.8294 0 TD
(E)Tj
/F10 1 Tf
.8006 0 TD
()Tj
/F4 1 Tf
.9388 0 TD
[(2)16.2(0)0(,)-171.6(1],)]TJ
/F8 1 Tf
2.6552 0 TD
(k)Tj
/F10 1 Tf
.766 0 TD
(2)Tj
/F4 1 Tf
.9331 0 TD
([1)Tj
/F8 1 Tf
.8352 0 TD
(E)Tj
/F10 1 Tf
.8006 0 TD
()Tj
/F4 1 Tf
.9388 0 TD
-.0162 Tc
[(20)-16.2(,)-182(1)]TJ
/F8 1 Tf
1.9007 0 TD
0 Tc
(E)Tj
/F10 1 Tf
.8006 0 TD
()Tj
/F4 1 Tf
.9388 0 TD
(8].)Tj
/F10 1 Tf
-18.2871 -1.1174 TD
()Tj
/F4 1 Tf
1.0022 0 TD
-.0161 Tc
[(The)-225.7(unif)-16.1(o)10.5(rm)-220(d)-16.1(i)10.4(str)-16.1(i)10.4(buti)-16.1(o)10.4(ns)]TJ
/F8 1 Tf
10.1198 0 TD
0 Tc
(U)Tj
/F4 1 Tf
.9216 0 TD
-.0161 Tc
[(use)-16.1(d)-209.5(fo)-16.1(r)-208.3(t)0(h)-16.1(e)-209.5(ini)-16.1(t)10.2(ial)-224.7(c)-1.1(ondi)-16.1(t)10.2(i)0(ons)]TJ
-11.0414 -1.1116 TD
0 Tc
[(w)15.3(e)15(re)25.5(:)]TJ
/F8 1 Tf
4.2219 0 TD
(U)Tj
6.8899 0 0 6.8899 379.1621 597.5432 Tm
(A)Tj
/F10 1 Tf
9.843 0 0 9.843 386.6456 599.0172 Tm
(2)Tj
/F4 1 Tf
.9331 0 TD
([1)Tj
/F8 1 Tf
.8294 0 TD
(E)Tj
/F10 1 Tf
.8006 0 TD
()Tj
/F4 1 Tf
.9388 0 TD
-.0162 Tc
[(10)-16.2(,)-187.8(0)]TJ
/F14 1 Tf
1.9007 0 TD
0 Tc
(:)Tj
/F4 1 Tf
.2707 0 TD
(5],)Tj
/F8 1 Tf
1.2556 0 TD
(U)Tj
/F12 1 Tf
6.8899 0 0 6.8899 461.877 597.5432 Tm
(b)Tj
/F10 1 Tf
9.843 0 0 9.843 468.907 599.0172 Tm
(2)Tj
/F4 1 Tf
.9388 0 TD
([1)Tj
/F8 1 Tf
.8294 0 TD
(E)Tj
/F10 1 Tf
.8006 0 TD
()Tj
/F4 1 Tf
.9388 0 TD
-.0162 Tc
[(10)-16.2(,)-187.8(1)]TJ
/F8 1 Tf
1.9007 0 TD
0 Tc
(E)Tj
/F10 1 Tf
.8006 0 TD
()Tj
/F4 1 Tf
.9388 0 TD
(5],)Tj
/F8 1 Tf
-21.2072 -1.1116 TD
(U)Tj
6.8899 0 0 6.8899 337.6062 586.6014 Tm
(s)Tj
/F10 1 Tf
9.843 0 0 9.843 343.5023 588.0754 Tm
(2)Tj
/F4 1 Tf
.9331 0 TD
([1)Tj
/F8 1 Tf
.8352 0 TD
(E)Tj
/F10 1 Tf
.8006 0 TD
()Tj
/F4 1 Tf
.9331 0 TD
[(5,)-171.6(1)16.2(0],)]TJ
/F8 1 Tf
2.6552 0 TD
(U)Tj
6.8899 0 0 6.8899 411.1936 586.6014 Tm
(k)Tj
/F10 1 Tf
9.843 0 0 9.843 417.6566 588.0754 Tm
(2)Tj
/F4 1 Tf
.9331 0 TD
[([1,)-166.9(5)]TJ
/F8 1 Tf
1.751 0 TD
(E)Tj
/F10 1 Tf
.8006 0 TD
()Tj
/F4 1 Tf
.9331 0 TD
(3])Tj
/F14 1 Tf
.8352 0 TD
(:)Tj
/F4 1 Tf
-15.0904 -1.7221 TD
[(Parameters)-350.7(in)-347.9(the)-350.2(mathematical)-350.3(model)-353.6(of)-347.7(the)-344.4(HIV/AIDS)]TJ
-1.0137 -1.1116 TD
[(infection)-340.9(are)-333.9(related)-339.7(to)-342.2(the)-332.9(immunological)-342.2(status)-341.7(of)-336.2(the)-338.7(pa-)]TJ
0 -1.1174 TD
[(tient.)-367.6(For)-366(instance,)]TJ
/F8 1 Tf
8.0693 0 TD
(s)Tj
/F4 1 Tf
.7545 0 TD
[(is)-365(the)-373.2(natural)-367.4(production)-369.5(rate)-369.7(of)-370.8(CD4)]TJ
-8.8239 -1.1116 TD
[(T)-261.5(cells)-261.3(by)-261.4(the)-258(thymus.)-264.6(So,)-258.9(a)-261.4(low)-263.5(value)-261.4(for)]TJ
/F8 1 Tf
17.0833 0 TD
(s)Tj
/F4 1 Tf
.6451 0 TD
[(is)-261.3(representative)]TJ
-17.7284 -1.1116 TD
[(of)-244.1(a)-244.2(badly)-248.7(damaged)-248.6(immune)-246.5(system.)-248.3(Similarly,)-246.5(a)-249.9(large)-244.1(value)]TJ
0 -1.1174 TD
(for)Tj
/F8 1 Tf
1.6358 0 TD
(A)Tj
/F4 1 Tf
1.0828 0 TD
[(indicates)-474.4(an)-469.9(important)-473.4(activation-induced)-481.3(apoptosis)]TJ
-2.7186 -1.1116 TD
(phenomenon.)Tj
1.0137 -1.1116 TD
[(When)-232.5(th)20.7(e)-221.1(a)0(p)19.7(o)0(p)15.1(t)0(o)20.7(s)0(i)20.9(s)-219.8(ph)15.1(en)19.7(om)19.6(en)19.7(on)-209.5(is)-215.2(no)20.8(t)-220.1(c)0(o)19.7(n)0(s)15.3(i)0(d)20.7(e)0(r)19.7(e)0(d)19.7(,)-222.3(an)-210.7(au)19.7(x-)]TJ
-1.0137 -1.1174 TD
[(il)20.6(ia)19.6(ry)-514.8(ma)18.4(th)20.7(em)18.5(at)19.5(ic)19.6(al)-521.9(ch)19.7(ar)19.7(ac)18.5(te)19.6(ri)20.7(za)18.5(ti)20.6(on)-514.8(of)-520.5(th)20.7(e)-526.4(i)0(m)19.5(m)0(u)19.6(n)0(o)20.8(l)0(o)20.7(g)0(i)20.7(c)0(a)18.5(l)]TJ
0 -1.1116 TD
[(fa)19.7(il)20.6(ur)20.9(e)-198.1(c)0(a)18.5(n)-196.9(be)-181.9(st)15.1(at)19.5(ed)-181.9(us)15.3(in)20.7(g)-191.2(t)0(h)14.9(e)-192.3(id)20.7(en)19.7(ti)14.8(e)19.8(d)-191.2(p)0(a)19.7(r)0(a)14(m)15(et)13.8(er)19.7(s)-191(a)0(s)-187.5(f)0(o)20.9(l)0(l)14.8(o)0(w)20(s)0(.)]TJ
1.0137 -1.1116 TD
[(The)-385.8(immune)-384.8(potential)-387.1(is)-388(given)-386.9(by)-382.3(the)-384.7(maximal)-392.9(level)-388.2(of)]TJ
-1.0137 -1.1116 TD
(CD4)Tj
/F7 1 Tf
7.3823 0 0 6.5614 330.633 454.9605 Tm
(+)Tj
/F4 1 Tf
9.843 0 0 9.843 339.0802 450.5952 Tm
[(T)-313.3(cells)-324.7(that)-316.9(can)-316.7(be)-320.1(reached)-323.4(if)-319.1(a)-313.3(100%)-322.3(efcient)-317.6(treat-)]TJ
-2.8683 -1.1174 TD
[(ment)-260.4(is)-261.3(administered.)-263.4(This)-264.7(maximal)-260.4(level)-261.5(is)-261.3(obtained)-264.8(by)-261.4(set-)]TJ
0 -1.1116 TD
(ting)Tj
/F8 1 Tf
1.8258 0 TD
(V)Tj
/F7 1 Tf
.7833 0 TD
(=)Tj
/F4 1 Tf
.72 0 TD
[(0)-260.3(i)0(n)-267.3(Equation)-264.9(1)-266(and)-263.6(computing)-271.8(its)-262.6(equilibrium)-268.4(point)]TJ
-3.3291 -1.1116 TD
(as)Tj
/F15 1 Tf
1.1462 0 TD
(D)Tj
/F4 1 Tf
6.8899 0 0 6.8899 328.7054 416.2393 Tm
(max)Tj
/F7 1 Tf
9.843 0 0 9.843 342.7653 417.7133 Tm
(=)Tj
ET
351.496 419.981 3.4583 .34015 re
f
BT
/F4 1 Tf
6.8899 0 0 6.8899 351.8928 421.2849 Tm
(s)Tj
/F11 1 Tf
-.0576 -1.0121 TD
(d)Tj
/F14 1 Tf
9.843 0 0 9.843 356.5983 417.7133 Tm
(:)Tj
/F4 1 Tf
.5875 0 TD
[(So,)-316.5(patients)-316.6(with)-322.3(a)-313.3(normal)-320.1(function)-321.2(of)-313.2(the)-321.4(thy-)]TJ
-5.2356 -1.1174 TD
[(mus)-298.1(must)-305.1(have)-300.5(a)]TJ
/F15 1 Tf
7.1593 0 TD
(D)Tj
/F4 1 Tf
7.3823 0 0 6.5614 387.8928 405.0708 Tm
(max)Tj
/F7 1 Tf
9.843 0 0 9.843 402.2928 406.7148 Tm
(>)Tj
/F4 1 Tf
.72 0 TD
[(200)-297.1(CD4/mm)]TJ
7.3823 0 0 6.5614 463.8046 411.0802 Tm
(3)Tj
9.843 0 0 9.843 467.4896 406.7148 Tm
(.)Tj
-14.9004 -1.1116 TD
[(But)-430.7(in)-428.5(practice,)-437.6(it)-428.7(is)-434.1(desirable)-433.9(to)-434.3(reach)-435.2(the)-430.8(equilibrium)]TJ
/F15 1 Tf
-1.0137 -1.1116 TD
(D)Tj
/F4 1 Tf
7.3823 0 0 6.5614 317.4235 383.1873 Tm
(max)Tj
9.843 0 0 9.843 332.7306 384.8314 Tm
[(within)-267.1(a)-261.4(reasonable)-263.2(time)-260.5(\(around)-262.2(6)-260.3(months)-261.2(in)-261.5(general\).)]TJ
-2.2232 -1.1174 TD
[(Thus,)-354.4(a)-347.8(more)-358.1(restrictive)-355.7(evaluation)-354.7(of)-353.5(the)-350.2(status)-353.2(of)-353.5(the)-355.9(im-)]TJ
0 -1.1116 TD
[(mune)-329.3(system)-337(is)-330.4(provided)-338.4(by)-330.5(the)-332.9(time)]TJ
/F8 1 Tf
15.5858 0 TD
(t)Tj
/F4 1 Tf
7.3823 0 0 6.5614 466.9794 361.2472 Tm
(200)Tj
9.843 0 0 9.843 481.3794 362.8912 Tm
[(required)-333.7(to)-330.6(reach)]TJ
-17.3252 -1.1116 TD
[(the)-453.8(critical)-450.5(threshold)-454.6(of)-451.4(200)-452.6(CD4/mm)]TJ
7.3823 0 0 6.5614 469.1337 356.3149 Tm
(3)Tj
9.843 0 0 9.843 472.8188 351.9495 Tm
[(.)-452.7(For)-452.4(patients)-454.8(who)]TJ
-16.4555 -1.1174 TD
[(are)-305.1(not)-302.9(in)-301.8(immunolog)-6.9(ical)-300.7(failur)-8(e,)]TJ
/F8 1 Tf
13.7657 0 TD
(t)Tj
/F4 1 Tf
7.3823 0 0 6.5614 449.1211 339.3637 Tm
(200)Tj
9.843 0 0 9.843 463.2377 340.9511 Tm
[(is)-301.6(less)-304.8(than)-305.2(6)-306.4(months.)]TJ
-15.4821 -1.1116 TD
[(More)-415.4(generally,)]TJ
/F8 1 Tf
6.9865 0 TD
(t)Tj
/F15 1 Tf
7.3823 0 0 6.5614 382.3936 328.3653 Tm
(D)Tj
/F4 1 Tf
9.843 0 0 9.843 391.4078 330.0094 Tm
[(denotes)-418.9(the)-413.5(time)-416(required)-420.1(to)-411.3(reach)-423.7(the)]TJ
-8.1845 -1.1116 TD
(level)Tj
/F15 1 Tf
2.2463 0 TD
(D)Tj
/F4 1 Tf
.9504 0 TD
[(of)-290.1(CD4)-287.4(T)-284.5(cells)-290.1(count)-289(in)-284.6(the)-292.6(case)-289.9(of)-284.4(a)-290.2(100%)-287.7(efcacy)]TJ
-3.1966 -1.1116 TD
[(of)-301.7(the)-298.3(therapy.)]TJ
/F8 1 Tf
6.2205 0 TD
(t)Tj
/F15 1 Tf
7.3823 0 0 6.5614 374.8534 306.4818 Tm
(D)Tj
/F4 1 Tf
9.843 0 0 9.843 382.7338 308.1259 Tm
[(is)-301.6(computed)-306.2(as)-296.9(follows)]TJ
7.3823 0 0 6.5614 474.8597 312.4913 Tm
(17)Tj
9.843 0 0 9.843 482.2865 308.1259 Tm
(:)Tj
/F8 1 Tf
-16.4036 -2.3672 TD
(t)Tj
/F15 1 Tf
6.8899 0 0 6.8899 323.5464 283.2944 Tm
(D)Tj
/F7 1 Tf
9.843 0 0 9.843 330.2928 284.8251 Tm
(=)Tj
/F4 1 Tf
.887 0 TD
(max)Tj
ET
363.401 287.036 4.9323 .39685 re
f
BT
9.843 0 0 9.843 363.4015 291.5149 Tm
(1)Tj
/F11 1 Tf
0 -1.3708 TD
(d)Tj
/F10 1 Tf
1.1923 .6912 TD
()Tj
/F4 1 Tf
1.1001 0 TD
(log)Tj
/F8 1 Tf
6.8899 0 0 6.8899 398.6078 282.3873 Tm
(e)Tj
/F4 1 Tf
9.843 0 0 9.843 407.7353 284.8251 Tm
(1)Tj
/F10 1 Tf
.6624 0 TD
()Tj
ET
1 i
q 1 0 0 1 425.14 287.433 cm 0 0 m
4.932 0 l
4.932 -.397 l
0 -.397 l
f*
Q
BT
/F11 1 Tf
9.843 0 0 9.843 425.14 291.5149 Tm
(d)Tj
/F8 1 Tf
.0576 -1.3708 TD
(s)Tj
/F15 1 Tf
.6105 .6912 TD
(D)Tj
/F16 1 Tf
-3.0008 1.4054 TD
2.9399 Tc
()Tj
/F10 1 Tf
4.5617 -1.4054 TD
0 Tc
()Tj
/F4 1 Tf
1.1059 0 TD
(log)Tj
/F8 1 Tf
6.8899 0 0 6.8899 470.5511 282.3873 Tm
(e)Tj
/F4 1 Tf
9.843 0 0 9.843 479.6786 284.8251 Tm
(1)Tj
/F10 1 Tf
.6681 0 TD
()Tj
ET
497.14 287.036 4.9323 .39685 re
f
BT
/F11 1 Tf
9.843 0 0 9.843 497.14 291.5149 Tm
(d)Tj
/F8 1 Tf
.0576 -1.3708 TD
(s)Tj
.6105 .6912 TD
(T)Tj
/F4 1 Tf
.6336 0 TD
(\(0\))Tj
/F16 1 Tf
-3.6344 1.4054 TD
4.0688 Tc
()Tj
-10.5863 0 TD
15.5957 Tc
()Tj
/F4 1 Tf
16.634 -1.4054 TD
.1705 Tc
(,0)Tj
/F16 1 Tf
-18.0509 1.4054 TD
18.2167 Tc
()Tj
/F4 1 Tf
18.5347 -3.5134 TD
0 Tc
(\(4\))Tj
-22.1115 -1.751 TD
[(Summarizing,)-371.8(patients)-380(are)-374.2(declared)-376.4(to)-376.7(be)-372(critical)-375.6(if)-376.7(they)]TJ
-1.0137 -1.1116 TD
[(belong)-301.6(to)-301.8(one)-298.2(of)-301.7(the)-298.3(following)-304.9(groups:)]TJ
/F10 1 Tf
.9964 -1.7222 TD
()Tj
/F4 1 Tf
1.0022 0 TD
[(A)-284.2(low)-286.5(value)-290.2(of)-284.4(the)-286.8(parameter)]TJ
/F8 1 Tf
12.1875 0 TD
(s)Tj
/F4 1 Tf
.6739 0 TD
(\()Tj
/F8 1 Tf
.3341 0 TD
(s)Tj
/F7 1 Tf
.5472 0 TD
()Tj
/F4 1 Tf
.72 0 TD
[(3\))-284.4(and)-286.7(a)-284.5(high)-286.8(value)]TJ
-14.4626 -1.1174 TD
[(of)-301.7(the)-298.3(parameter)]TJ
/F8 1 Tf
6.9865 0 TD
(A)Tj
/F4 1 Tf
.91 0 TD
(\()Tj
/F8 1 Tf
.3341 0 TD
(A)Tj
/F7 1 Tf
.7833 0 TD
(>)Tj
/F4 1 Tf
.5645 0 TD
(10)Tj
/F10 1 Tf
7.3823 0 0 6.5614 434.6644 212.3716 Tm
()Tj
/F4 1 Tf
.7756 0 TD
(2)Tj
9.843 0 0 9.843 444.0755 207.9495 Tm
(\))Tj
/F10 1 Tf
-12.5389 -1.1116 TD
()Tj
/F15 1 Tf
1.0022 0 TD
(D)Tj
/F4 1 Tf
7.3823 0 0 6.5614 337.096 195.3637 Tm
(max)Tj
/F7 1 Tf
9.843 0 0 9.843 351.496 197.0078 Tm
(>)Tj
/F4 1 Tf
.72 0 TD
[(200)-302.8(CD4/mm)]TJ
7.3823 0 0 6.5614 413.0078 201.3732 Tm
(3)Tj
/F10 1 Tf
9.843 0 0 9.843 320.655 186.0661 Tm
()Tj
/F15 1 Tf
1.0022 0 TD
(D)Tj
/F4 1 Tf
7.3823 0 0 6.5614 337.096 184.422 Tm
(max)Tj
/F7 1 Tf
9.843 0 0 9.843 351.496 186.0661 Tm
(>)Tj
/F4 1 Tf
.72 0 TD
[(200)-302.8(CD4/mm)]TJ
7.3823 0 0 6.5614 413.0078 190.4315 Tm
(3)Tj
9.843 0 0 9.843 416.7495 186.0661 Tm
[(,)-297.2(but)]TJ
/F8 1 Tf
2.1311 0 TD
(t)Tj
/F4 1 Tf
7.3823 0 0 6.5614 440.4471 184.422 Tm
(200)Tj
/F7 1 Tf
9.843 0 0 9.843 453.203 186.0661 Tm
(>)Tj
/F4 1 Tf
.72 0 TD
[(6)-300.6(months)]TJ
/F13 1 Tf
8.9663 0 0 8.9663 310.8472 161.0078 Tm
(Results)Tj
/F4 1 Tf
9.843 0 0 9.843 320.8251 144.5669 Tm
[(To)-262.6(characterize)-280.7(critical)-266.2(patients,)-274(two)-269.2(identications)-272.6(of)-267.1(the)]TJ
-1.0137 -1.1116 TD
[(parameters)-419.9(were)-410.8(done)-414.5(using)-414.4(the)-413.5(data)-415.8(collected)-418.1(in)-411.3(the)-419.3(rst)]TJ
0 -1.1174 TD
[(month)-381.2(of)-382.3(the)-379(trial;)-388.4(that)-380.2(is,)-385.7(the)-379(rst)-384.3(seven)-382(or)-382.3(eight)-381.3(samples)]TJ
0 -1.1116 TD
[(were)-502.9(used.)-498.4(The)-501(rst)-499.5(identication)-502.1(only)-499.9(considered)-498.2(a)-503.4(de-)]TJ
T*
[(graded)-435.1(functionality)-432(of)-434.1(the)-430.8(thymus;)-435.2(that)-432(is,)-431.8(the)-436.6(parameter)]TJ
/F8 1 Tf
0 -1.1174 TD
(A)Tj
/F4 1 Tf
1.0137 0 TD
[(was)-396.8(taken)-399.6(equal)-399.6(to)-399.7(zero.)-401.8(The)-397.3(second)-400.4(identication)-404.2(took)]TJ
-1.0137 -1.1116 TD
[(into)-384.8(account)-391.5(the)-390.5(activation-induced)-389.1(apoptosis)-391.1(phenomenon)]TJ
T*
[(but)-343.3(a)-347.8(normal)-348.9(thymic)-349.1(function)-350(\()]TJ
/F8 1 Tf
12.7693 0 TD
(s)Tj
/F7 1 Tf
.5529 0 TD
(=)Tj
/F4 1 Tf
.72 0 TD
.1681 Tc
[(6m)168.1(m)]TJ
7.3823 0 0 6.5614 471.0046 71.2063 Tm
0 Tc
(3)Tj
9.843 0 0 9.843 474.6896 67.8614 Tm
[(/d\).)-352.4(The)-345.5(numerical)]TJ
-16.6455 -1.1116 TD
[(results)-532.8(of)-526.3(the)-534.5(identication)-530.9(of)-532.1(the)-528.7(parameters)]TJ
/F8 1 Tf
20.1532 0 TD
(s)Tj
/F10 1 Tf
.3859 0 TD
(j)Tj
/F8 1 Tf
7.3823 0 0 6.5614 515.6786 55.2756 Tm
(A)Tj
/F7 1 Tf
.7833 0 TD
(=)Tj
/F4 1 Tf
.7219 0 TD
(0)Tj
9.843 0 0 9.843 535.6912 56.9197 Tm
(and)Tj
ET
/Document /MC1 BDC
0 0 0 1 K
0 J 1 j .495 w 10 M []0 d
/GS2 gs
q 1 0 0 1 83.194 269.324 cm 0 0 m
0 -2.072 l
S 1 0 0 1 0 -166.704 cm 0 0 m
0 2.109 l
S 1 0 0 1 0 0 cm 0 0 m
0 166.704 l
S 1 0 0 1 0 0 cm 0 0 m
208.295 0 l
S 1 0 0 1 0 0 cm 0 0 m
0 166.704 l
S 1 0 0 1 208.295 0 cm 0 0 m
0 166.704 l
S 1 0 0 1 -208.295 0 cm 0 0 m
208.295 0 l
S 1 0 0 1 0 166.704 cm 0 0 m
208.295 0 l
S
Q
BT
/F17 1 Tf
6.9678 0 0 6.9679 81.2698 96.1446 Tm
.69763 .67523 .63858 .73956 k
(0)Tj
ET
q 1 0 0 1 124.823 269.324 cm 0 0 m
0 -2.072 l
S 1 0 0 1 0 -166.704 cm 0 0 m
0 2.109 l
S
Q
BT
6.9678 0 0 6.9679 120.9483 96.1446 Tm
(20)Tj
ET
q 1 0 0 1 166.49 269.324 cm 0 0 m
0 -2.072 l
S 1 0 0 1 0 -166.704 cm 0 0 m
0 2.109 l
S
Q
BT
6.9678 0 0 6.9679 162.6152 96.1446 Tm
(40)Tj
ET
q 1 0 0 1 208.157 269.324 cm 0 0 m
0 -2.072 l
S 1 0 0 1 0 -166.704 cm 0 0 m
0 2.109 l
S
Q
BT
6.9678 0 0 6.9679 204.2829 96.1446 Tm
(60)Tj
ET
q 1 0 0 1 249.824 269.324 cm 0 0 m
0 -2.072 l
S 1 0 0 1 0 -166.704 cm 0 0 m
0 2.109 l
S
Q
BT
6.9678 0 0 6.9679 245.9487 96.1446 Tm
(80)Tj
ET
q 1 0 0 1 291.49 269.324 cm 0 0 m
0 -2.072 l
S 1 0 0 1 0 -166.704 cm 0 0 m
0 2.109 l
S
Q
BT
6.9678 0 0 6.9679 285.7165 96.1446 Tm
(100)Tj
ET
q 1 0 0 1 291.49 109.061 cm 0 0 m
-2.108 0 l
S 1 0 0 1 -208.295 0 cm 0 0 m
2.073 0 l
S
Q
BT
6.9678 0 0 6.9679 71.4881 106.7296 Tm
(1.5)Tj
ET
q 1 0 0 1 291.49 125.073 cm 0 0 m
-2.108 0 l
S 1 0 0 1 -208.295 0 cm 0 0 m
2.073 0 l
S
Q
BT
6.9678 0 0 6.9679 77.2991 122.7365 Tm
(2)Tj
ET
q 1 0 0 1 291.49 141.119 cm 0 0 m
-2.108 0 l
S 1 0 0 1 -208.295 0 cm 0 0 m
2.073 0 l
S
Q
BT
6.9678 0 0 6.9679 71.4881 138.7844 Tm
(2.5)Tj
ET
q 1 0 0 1 291.49 157.132 cm 0 0 m
-2.108 0 l
S 1 0 0 1 -208.295 0 cm 0 0 m
2.073 0 l
S
Q
BT
6.9678 0 0 6.9679 77.2991 154.7953 Tm
(3)Tj
ET
q 1 0 0 1 291.49 173.182 cm 0 0 m
-2.108 0 l
S 1 0 0 1 -208.295 0 cm 0 0 m
2.073 0 l
S
Q
BT
6.9678 0 0 6.9679 71.4881 170.8502 Tm
(3.5)Tj
ET
q 1 0 0 1 291.49 189.192 cm 0 0 m
-2.108 0 l
S 1 0 0 1 -208.295 0 cm 0 0 m
2.073 0 l
S
Q
BT
6.9678 0 0 6.9679 77.2991 186.8595 Tm
(4)Tj
ET
q 1 0 0 1 291.49 205.241 cm 0 0 m
-2.108 0 l
S 1 0 0 1 -208.295 0 cm 0 0 m
2.073 0 l
S
Q
BT
6.9678 0 0 6.9679 71.4881 202.9087 Tm
(4.5)Tj
ET
q 1 0 0 1 291.49 221.253 cm 0 0 m
-2.108 0 l
S 1 0 0 1 -208.295 0 cm 0 0 m
2.073 0 l
S
Q
BT
6.9678 0 0 6.9679 77.2991 218.9223 Tm
(5)Tj
ET
q 1 0 0 1 291.49 237.302 cm 0 0 m
-2.108 0 l
S 1 0 0 1 -208.295 0 cm 0 0 m
2.073 0 l
S
Q
BT
6.9678 0 0 6.9679 71.4881 234.9715 Tm
(5.5)Tj
ET
q 1 0 0 1 291.49 253.313 cm 0 0 m
-2.108 0 l
S 1 0 0 1 -208.295 0 cm 0 0 m
2.073 0 l
S
Q
BT
6.9678 0 0 6.9679 77.2991 250.9763 Tm
(6)Tj
ET
q 1 0 0 1 291.49 269.324 cm 0 0 m
-2.108 0 l
S 1 0 0 1 -208.295 0 cm 0 0 m
2.073 0 l
S
Q
BT
6.9678 0 0 6.9679 71.4881 266.9914 Tm
(6.5)Tj
ET
q 1 0 0 1 83.194 102.62 cm 0 0 m
0 166.704 l
S 1 0 0 1 208.295 0 cm 0 0 m
0 166.704 l
S 1 0 0 1 -208.295 0 cm 0 0 m
208.295 0 l
S 1 0 0 1 0 166.704 cm 0 0 m
208.295 0 l
S
Q
.88003 .7637 .003235 .000031 K
q 1 0 0 1 83.194 253.313 cm 0 0 m
2.073 3.842 l
4.144 -11.226 l
8.326 -25.655 l
22.907 -64.421 l
43.739 -81.11 l
58.319 -84.652 l
93.732 -106.766 l
124.963 -109.329 l
154.123 -109.329 l
189.536 -118.633 l
S
Q
0 j
q 1 0 0 1 271.639 135.77 cm 0 0 m
0 0 2.183 -2.184 re
S 1 0 0 1 -35.416 9.307 cm 0 0 m
0 0 2.187 -2.185 re
S 1 0 0 1 -29.158 0 cm 0 0 m
0 0 2.185 -2.185 re
S 1 0 0 1 -31.232 2.562 cm 0 0 m
0 0 2.186 -2.186 re
S 1 0 0 1 -35.413 22.113 cm 0 0 m
0 0 2.1851 -2.184 re
S 1 0 0 1 -14.58 3.543 cm 0 0 m
0 0 2.1856 -2.1859 re
S 1 0 0 1 -20.833 16.689 cm 0 0 m
0 0 2.1851 -2.186 re
S 1 0 0 1 -14.58 38.765 cm 0 0 m
0 0 2.1856 -2.1846 re
S 1 0 0 1 -4.182 14.429 cm 0 0 m
0 0 2.1851 -2.1851 re
S 1 0 0 1 -2.072 15.069 cm 0 0 m
0 0 2.1856 -2.1851 re
S 1 0 0 1 -2.072 -3.842 cm 0 0 m
0 0 2.185 -2.1855 re
S
Q
.87579 .24982 1 .11521 K
q 1 0 0 1 83.194 206.522 cm 0 0 m
2.073 .301 l
4.144 -8.664 l
14.58 -43.287 l
27.051 -59.336 l
43.739 -74.064 l
62.464 -94.258 l
189.536 -94.258 l
S
Q
.87579 .24982 1 .11521 k
q 1 0 0 1 83.66 206.501 cm 0 0 m
0 -.25 -.203 -.453 -.452 -.453 c
-.702 -.453 -.904 -.25 -.904 0 c
-.904 .25 -.702 .452 -.452 .452 c
-.203 .452 0 .25 0 0 c
f
Q
q 1 0 0 1 85.722 206.826 cm 0 0 m
0 -.249 -.203 -.452 -.453 -.452 c
-.702 -.452 -.905 -.249 -.905 0 c
-.905 .251 -.702 .453 -.453 .453 c
-.203 .453 0 .251 0 0 c
f
Q
q 1 0 0 1 87.783 197.821 cm 0 0 m
0 -.249 -.203 -.452 -.453 -.452 c
-.702 -.452 -.904 -.249 -.904 0 c
-.904 .249 -.702 .452 -.453 .452 c
-.203 .452 0 .249 0 0 c
f
Q
q 1 0 0 1 98.254 163.21 cm 0 0 m
0 -.25 -.203 -.453 -.453 -.453 c
-.702 -.453 -.904 -.25 -.904 0 c
-.904 .249 -.702 .452 -.453 .452 c
-.203 .452 0 .249 0 0 c
f
Q
q 1 0 0 1 110.731 147.151 cm 0 0 m
0 -.249 -.203 -.452 -.453 -.452 c
-.702 -.452 -.905 -.249 -.905 0 c
-.905 .249 -.702 .452 -.453 .452 c
-.203 .452 0 .249 0 0 c
f
Q
q 1 0 0 1 127.385 132.45 cm 0 0 m
0 -.25 -.202 -.452 -.452 -.452 c
-.702 -.452 -.905 -.25 -.905 0 c
-.905 .249 -.702 .451 -.452 .451 c
-.202 .451 0 .249 0 0 c
f
Q
q 1 0 0 1 146.102 112.27 cm 0 0 m
0 -.25 -.204 -.453 -.453 -.453 c
-.702 -.453 -.905 -.25 -.905 0 c
-.905 .25 -.702 .452 -.453 .452 c
-.204 .452 0 .25 0 0 c
f
Q
q 1 0 0 1 177.35 112.27 cm 0 0 m
0 -.25 -.203 -.453 -.453 -.453 c
-.702 -.453 -.905 -.25 -.905 0 c
-.905 .25 -.702 .452 -.453 .452 c
-.203 .452 0 .25 0 0 c
f
Q
q 1 0 0 1 212.72 112.27 cm 0 0 m
0 -.25 -.201 -.453 -.452 -.453 c
-.701 -.453 -.903 -.25 -.903 0 c
-.903 .25 -.701 .452 -.452 .452 c
-.201 .452 0 .25 0 0 c
f
Q
q 1 0 0 1 241.96 112.27 cm 0 0 m
0 -.25 -.202 -.453 -.45 -.453 c
-.702 -.453 -.902 -.25 -.902 0 c
-.902 .25 -.702 .452 -.45 .452 c
-.202 .452 0 .25 0 0 c
f
Q
q 1 0 0 1 273.155 112.27 cm 0 0 m
0 -.25 -.203 -.453 -.452 -.453 c
-.701 -.453 -.904 -.25 -.904 0 c
-.904 .25 -.701 .452 -.452 .452 c
-.203 .452 0 .25 0 0 c
f
Q
.004669 .9859 .97497 .000946 K
q 1 0 0 1 83.194 230.859 cm 0 0 m
2.073 8.025 l
4.144 -7.986 l
14.58 -.64 l
27.051 -43.588 l
41.629 -48.711 l
56.21 -51.273 l
99.948 -69.883 l
129.107 -75.95 l
164.521 -75.309 l
187.464 -82.694 l
S 1 0 0 1 188.857 -82.677 cm 0 0 m
0 -.749 -.607 -1.357 -1.357 -1.357 c
-2.107 -1.357 -2.712 -.749 -2.712 0 c
-2.712 .749 -2.107 1.356 -1.357 1.356 c
-.607 1.356 0 .749 0 0 c
S 1 0 0 1 -23.003 7.378 cm 0 0 m
0 -.748 -.607 -1.356 -1.355 -1.356 c
-2.104 -1.356 -2.712 -.748 -2.712 0 c
-2.712 .749 -2.104 1.357 -1.355 1.357 c
-.607 1.357 0 .749 0 0 c
S 1 0 0 1 -35.37 -.65 cm 0 0 m
0 -.75 -.607 -1.357 -1.356 -1.357 c
-2.105 -1.357 -2.711 -.75 -2.711 0 c
-2.711 .748 -2.105 1.357 -1.356 1.357 c
-.607 1.357 0 .748 0 0 c
S 1 0 0 1 -29.187 6.076 cm 0 0 m
0 -.75 -.608 -1.357 -1.356 -1.357 c
-2.105 -1.357 -2.712 -.75 -2.712 0 c
-2.712 .747 -2.105 1.356 -1.356 1.356 c
-.608 1.356 0 .747 0 0 c
S 1 0 0 1 -43.725 18.552 cm 0 0 m
0 -.748 -.607 -1.354 -1.357 -1.354 c
-2.105 -1.354 -2.712 -.748 -2.712 0 c
-2.712 .75 -2.105 1.357 -1.357 1.357 c
-.607 1.357 0 .75 0 0 c
S 1 0 0 1 -14.539 2.605 cm 0 0 m
0 -.75 -.609 -1.357 -1.356 -1.357 c
-2.105 -1.357 -2.713 -.75 -2.713 0 c
-2.713 .748 -2.105 1.355 -1.356 1.355 c
-.609 1.355 0 .748 0 0 c
S 1 0 0 1 -14.648 5.099 cm 0 0 m
0 -.749 -.607 -1.357 -1.356 -1.357 c
-2.105 -1.357 -2.713 -.749 -2.713 0 c
-2.713 .749 -2.105 1.356 -1.356 1.356 c
-.607 1.356 0 .749 0 0 c
S 1 0 0 1 -12.478 42.966 cm 0 0 m
0 -.749 -.607 -1.357 -1.356 -1.357 c
-2.105 -1.357 -2.712 -.749 -2.712 0 c
-2.712 .749 -2.105 1.356 -1.356 1.356 c
-.607 1.356 0 .749 0 0 c
S 1 0 0 1 -10.416 -7.378 cm 0 0 m
0 -.749 -.607 -1.356 -1.356 -1.356 c
-2.104 -1.356 -2.712 -.749 -2.712 0 c
-2.712 .749 -2.104 1.356 -1.356 1.356 c
-.607 1.356 0 .749 0 0 c
S 1 0 0 1 -2.061 16.058 cm 0 0 m
0 -.749 -.607 -1.356 -1.356 -1.356 c
-2.105 -1.356 -2.712 -.749 -2.712 0 c
-2.712 .749 -2.105 1.356 -1.356 1.356 c
-.607 1.356 0 .749 0 0 c
S 1 0 0 1 -2.061 -8.029 cm 0 0 m
0 -.748 -.608 -1.356 -1.357 -1.356 c
-2.106 -1.356 -2.713 -.748 -2.713 0 c
-2.713 .749 -2.106 1.357 -1.357 1.357 c
-.608 1.357 0 .749 0 0 c
S
Q
0 0 0 1 K
q 1 0 0 1 83.194 233.421 cm 0 0 m
8.326 -25.957 l
16.652 -46.452 l
18.724 -51.913 l
22.907 -55.757 l
29.159 -66.343 l
35.376 -72.445 l
62.464 -83.334 l
97.876 -84.614 l
124.963 -94.862 l
189.536 -121.158 l
S 1 0 0 1 189.536 -119.802 cm 0 0 m
0 -2.712 l
S 1 0 0 1 -1.357 -1.356 cm 0 0 m
2.711 0 l
S 1 0 0 1 -63.217 27.652 cm 0 0 m
0 -2.713 l
S 1 0 0 1 -1.354 -1.356 cm 0 0 m
2.713 0 l
S 1 0 0 1 -25.733 11.604 cm 0 0 m
0 -2.713 l
S 1 0 0 1 -1.356 -1.356 cm 0 0 m
2.712 0 l
S 1 0 0 1 -34.056 2.636 cm 0 0 m
0 -2.714 l
S 1 0 0 1 -1.357 -1.356 cm 0 0 m
2.713 0 l
S 1 0 0 1 -25.731 12.243 cm 0 0 m
0 -2.712 l
S 1 0 0 1 -1.356 -1.354 cm 0 0 m
2.712 0 l
S 1 0 0 1 -4.86 7.458 cm 0 0 m
0 -2.712 l
S 1 0 0 1 -1.356 -1.356 cm 0 0 m
2.712 0 l
S 1 0 0 1 -4.896 11.942 cm 0 0 m
0 -2.713 l
S 1 0 0 1 -1.357 -1.356 cm 0 0 m
2.713 0 l
S 1 0 0 1 -2.825 5.199 cm 0 0 m
0 -2.713 l
S 1 0 0 1 -1.356 -1.355 cm 0 0 m
2.712 0 l
S 1 0 0 1 -.716 6.818 cm 0 0 m
0 -2.712 l
S 1 0 0 1 -1.356 -1.356 cm 0 0 m
2.712 0 l
S 1 0 0 1 -6.97 21.85 cm 0 0 m
0 -2.712 l
S 1 0 0 1 -1.356 -1.356 cm 0 0 m
2.712 0 l
S 1 0 0 1 -6.97 27.313 cm 0 0 m
0 -2.712 l
S 1 0 0 1 -1.356 -1.356 cm 0 0 m
2.712 0 l
S
Q
BT
6.9678 0 0 6.9679 170.6961 87.2957 Tm
.69763 .67523 .63858 .73956 k
(Time \(day\))Tj
0 6.9678 -6.9679 -0 67.327 146.4824 Tm
(Viral load \(log\(copies/ml\)\))Tj
ET
0 0 0 0 k
195.084 206.786 46.112 29.612 re
f
0 0 0 0 K
.323 w
q 1 0 0 1 195.084 206.786 cm 0 0 m
0 29.612 l
46.112 29.612 l
46.112 0 l
0 0 l
S
Q
0 0 0 1 K
.495 w
q 1 0 0 1 195.084 206.786 cm 0 0 m
0 29.612 l
S 1 0 0 1 57.545 0 cm 0 0 m
0 29.612 l
S 1 0 0 1 -57.545 0 cm 0 0 m
57.545 0 l
S 1 0 0 1 0 29.612 cm 0 0 m
57.545 0 l
S 1 0 0 1 0 -29.612 cm 0 0 m
0 29.612 l
S 1 0 0 1 0 0 cm 0 0 m
57.545 0 l
S 1 0 0 1 0 0 cm 0 0 m
0 29.612 l
S 1 0 0 1 57.545 0 cm 0 0 m
0 29.612 l
S 1 0 0 1 -57.545 0 cm 0 0 m
57.545 0 l
S 1 0 0 1 0 29.612 cm 0 0 m
57.545 0 l
S
Q
BT
6.9678 0 0 6.9679 212.7139 230.1854 Tm
.69763 .67523 .63858 .73956 k
.0001 Tw
(Patient 01x)Tj
ET
.88003 .7637 .003235 .000031 K
q 1 0 0 1 203.487 233.195 cm 0 0 m
0 0 2.184 -2.1851 re
S 1 0 0 1 -5.691 -1.092 cm 0 0 m
13.564 0 l
S
Q
BT
6.9678 0 0 6.9679 212.7139 223.1733 Tm
(Patient 02x)Tj
ET
.87579 .24982 1 .11521 K
q 1 0 0 1 197.796 225.096 cm 0 0 m
13.564 0 l
S
Q
.87579 .24982 1 .11521 k
q 1 0 0 1 205.018 225.109 cm 0 0 m
0 -.249 -.203 -.452 -.453 -.452 c
-.703 -.452 -.906 -.249 -.906 0 c
-.906 .249 -.703 .452 -.453 .452 c
-.203 .452 0 .249 0 0 c
f
Q
BT
6.9678 0 0 6.9679 212.7139 216.1318 Tm
.69763 .67523 .63858 .73956 k
(Patient 04x)Tj
ET
.004669 .9859 .97497 .000946 K
q 1 0 0 1 205.975 218.056 cm 0 0 m
0 -.748 -.608 -1.356 -1.356 -1.356 c
-2.105 -1.356 -2.713 -.748 -2.713 0 c
-2.713 .748 -2.105 1.356 -1.356 1.356 c
-.608 1.356 0 .748 0 0 c
S 1 0 0 1 -8.179 .032 cm 0 0 m
13.564 0 l
S
Q
BT
6.9678 0 0 6.9679 212.7139 209.1245 Tm
(Patient 06x)Tj
ET
0 0 0 1 K
q 1 0 0 1 204.577 212.437 cm 0 0 m
0 -2.712 l
S 1 0 0 1 -1.355 -1.357 cm 0 0 m
2.713 0 l
S 1 0 0 1 -5.426 0 cm 0 0 m
13.564 0 l
S
Q
EMC
/GS1 gs
BT
/F5 1 Tf
9.845 0 0 9.845 59.7543 66.8409 Tm
0 0 0 rg
0 Tw
[(FIG.)-451.9(1.)]TJ
/F4 1 Tf
4.2325 0 TD
[(Viral)-416.2(load)-419.9(time)-415.5(evolution)-419.5(for)-417.6(four)-412.8(patients.)-417.1(The)]TJ
-4.2325 -1.0135 TD
[(samples)-304(are)-304.8(taken)-301.2(frequently)-300.5(at)-302.8(the)-303.8(beginning)-298.3(of)-301.4(the)-298(trial.)]TJ
/F1 1 Tf
8.9663 0 0 8.9663 59.7543 749.5368 Tm
[(HIV)-301.4(DYNAMICS)-303.1(MODELING)-305(AFTER)-305.7(ANTIRETROVIRAL)-305.3(INITIATION)-21673.9(235)]TJ
ET
endstream
endobj
74 0 obj
<>stream
2014-09-24T08:03:24+05:30
Adobe Illustrator CS4
256
204
JPEG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=
False
False
1
70.157471
49.606689
Picas
Helvetica
Helvetica
Medium
Type 1
002.000
False
HV______.PFB; HV______.PFM
Cyan
Magenta
Yellow
Black
Default Swatch Group
0
application/postscript
converted
from application/postscript to application/vnd.adobe.illustrator
converted
from application/postscript to application/vnd.adobe.illustrator
converted
from application/postscript to application/vnd.adobe.illustrator
converted
from application/postscript to application/vnd.adobe.illustrator
endstream
endobj
71 0 obj
<>
endobj
75 0 obj
<>/XObject<>/ProcSet [/PDF /Text /ImageB /ImageC /ImageI]/Font<>>>/Thumb 77 0 R/MediaBox[0 0 612 792]/Rotate 0>>
endobj
78 0 obj
<>/ProcSet[/PDF/Text]/Font<>>>
endobj
76 0 obj
<>stream
/GS1 gs
BT
/F8 1 Tf
9.843 0 0 9.843 62.022 725.5557 Tm
0 0 0 rg
0 Tc
0 Tw
(A)Tj
/F10 1 Tf
.6163 0 TD
(j)Tj
/F8 1 Tf
7.3823 0 0 6.5614 70.7527 723.9116 Tm
(s)Tj
/F7 1 Tf
.5529 0 TD
(=)Tj
/F4 1 Tf
.7219 0 TD
(6)Tj
9.843 0 0 9.843 86.4566 725.5557 Tm
[(for)-262.4(each)-267.1(patient)-263.9(in)-267.3(the)-263.8(EDV05)-261.9(trial)-266.2(and)-263.7(the)-263.8(analy)-8(sis)-262.2(of)]TJ
-2.4824 -1.1174 TD
[(the)-436.6(remaining)-439.9(parameters)-437.2(of)-434.1(the)-436.6(dynamical)-441.1(model)-434.3(can)-437.6(be)]TJ
0 -1.1116 TD
[(found)-299.2(in)-301.8(previous)-303.6(articles.)]TJ
7.3823 0 0 6.5614 166.5637 707.981 Tm
(4,8,29)Tj
/F13 1 Tf
8.9663 0 0 8.9663 62.022 682.1857 Tm
(Discussion)Tj
/F4 1 Tf
9.843 0 0 9.843 72 665.7447 Tm
-.0155 Tc
[(I)-15.5(n)-351.7(Ri)-15.5(v)11(a)-.5(dene)-15.5(i)9.8(r).7(a)-340.3(e)-.5(t)-339.3(a)-.5(l.,)]TJ
7.3823 0 0 6.5614 154.7149 670.1667 Tm
-.0239 Tc
(29)Tj
9.843 0 0 9.843 165.1464 665.7447 Tm
.3239 Tc
[(t)340(h)340.1(el)340(a)338.9(s)323.9(t)10.7(c)338.9(o)340.1(l)340(u)340.1(m)338.9(no)340.1(ft)323.9(a)349.2(b)340.1(l)340(e)-.9(1d)340.1(i)340(s)323.9(p)350.7(l)340(a)338.9(y)340.1(s)]TJ
-10.4769 -1.1116 TD
-.0159 Tc
[(the)-490.5(t).2(heor)-15.9(e)9.6(tica)-15.9(l)-474.4(time)]TJ
/F8 1 Tf
8.4495 0 TD
0 Tc
(t)Tj
/F4 1 Tf
7.3823 0 0 6.5614 147.8551 653.1589 Tm
-.0239 Tc
[(20)-7.7(0)]TJ
9.843 0 0 9.843 163.2755 654.803 Tm
-.0155 Tc
[(necess)-15.5(a)10.1(ry)-483.1(t)-15.5(o)-472.8(reco)-15.5(v)11.1(e)-.5(r)-483.1(a)-484.3(C)-15.5(D)9.2(4)-483.1(l).6(ev)-15.5(e)9.9(l)]TJ
-10.2868 -1.1116 TD
0 Tc
[(a)15(b)16.2(ov)26.6(e)-238.4(2)16.2(00)-226.8(C)15.2(D)15.3(4/)26.5(m)15(m)]TJ
7.3823 0 0 6.5614 140.0314 648.2266 Tm
(3)Tj
9.843 0 0 9.843 143.5464 643.8613 Tm
-.0156 Tc
[(.)-255.2(T)-15.6(h)9.8(i).5(s)-252.6(t)-15.6(h)10.9(e)-.6(ore)-15.6(t)9.7(i).5(cal)-258.7(time)]TJ
/F8 1 Tf
8.7951 0 TD
0 Tc
(t)Tj
/F4 1 Tf
7.3823 0 0 6.5614 232.7243 642.2172 Tm
-.0239 Tc
[(20)-7.7(0)]TJ
9.843 0 0 9.843 245.8771 643.8613 Tm
-.0157 Tc
[(was)-258.5(c)-.7(omput)-15.7(e)9.6(d)]TJ
-18.6787 -1.1174 TD
[(fr)-15.7(o)10.9(m)-455.8(E)-15.7(q)9.7(uati)-15.7(o)10.8(n)-460.3(4)-454.5(u)-15.7(s)11.1(i).4(ng)-460.3(th)-15.7(e)-445.3(p)-15.7(a)9.7(r).5(amet)-15.7(e)9.6(r)-460.3(ident)-15.7(i)10.6(cat)-15.7(i)10.6(o).5(n)-460.3(metho)-15.7(d)]TJ
0 -1.1116 TD
[(bas)-15.8(e)9.8(d)-212.7(onl)-15.8(y)-202.4(o).4(n)-212.7(t)-15.8(h)10.7(e)-213.9(samp)-15.8(l)10.7(e)-.8(s)-212.5(f)-15.8(r)10.9(o).4(m)-214(t).3(he)-219.6(rst)-218.6(3)-212.7(w)-.5(eek)-15.8(s)-202.1(a)-.8(ft)-15.8(e)9.5(r)-212.7(ini)-15.8(t)10.5(iati)-15.8(o)10.7(n)]TJ
T*
-.0159 Tc
[(of)-287.7(the)-283.1(t)-15.9(h)10.6(e)-.9(rapy)-15.9(.)-273.9(A)-.6(ccord)-15.9(i)10.6(n).3(g)-281.9(t)-15.9(o)-271.7(t).2(his)-287.5(t).2(heo)-15.9(r)10.7(etic)-15.9(a)8.4(l)-282.1(tim)-15.9(e)]TJ
/F8 1 Tf
19.439 0 TD
0 Tc
(t)Tj
/F4 1 Tf
7.3823 0 0 6.5614 255.9684 609.3353 Tm
-.0162 Tc
[(20)7.7(0)]TJ
9.843 0 0 9.843 266.6267 610.9794 Tm
0 Tc
[(,)-268.4()16.3(v)16.2(e)-267.2(pa)25.4(-)]TJ
-20.7868 -1.1116 TD
-.0159 Tc
[(ti)-15.9(e)9.4(n).3(ts)-327.8(are)-329.2(predic)-15.9(t)9.4(ed)-322.3(t)-15.9(o)-312(be)-329.2(in)-328(immunol)-15.9(o)10.6(g).3(ical)-328.2(fai)-15.9(l)10.4(ure)-329.2(sinc)-15.9(e)-314.2(t).2(he)-15.9(y)]TJ
0 -1.1174 TD
0 Tc
[(w)15.3(i)16.1(ll)-192.5(n)16.2(o)0(t)-192.4(r)16.2(ec)24.3(o)16.2(v)16.2(e)15(r)-208.4(t)16.1(h)16.2(e)-209.6(d)16.2(e)15(s)16.4(i)16.1(re)25.5(d)-202.7(C)0(D)24.7(4)-202.7(l)16.1(e)0(v)25.4(e)15(l)-202.8(o)0(f)-192.2(2)16.2(00)-192.3(C)15.2(D)15.3(4/)26.5(m)15(m)]TJ
7.3823 0 0 6.5614 270.9354 593.4045 Tm
(3)Tj
9.843 0 0 9.843 276.6613 589.0392 Tm
-.0159 Tc
[(with)-15.9(i)10.6(n)]TJ
-21.8062 -1.1116 TD
0 Tc
[(6)-300.6(m)15(o)16.2(n)16.2(t)16.1(hs)26.8(.)-297.2(T)15(he)-285.6(r)16.2(e)0(m)24.2(a)15(i)16.1(n)16.2(i)16.1(n)0(g)-284.4(1)16.2(1)-300.6(p)16.2(at)25.3(i)16.1(e)15(n)16.2(t)16.1(s)-300.4(a)15(re)-285.6(pr)26.6(e)15(d)16.2(i)16.1(c)15(te)25.3(d)-300.6(t)16.1(o)-300.6(r)16.2(e)15(c)15(o)16.2(v)16.2(e)0(r)]TJ
T*
-.016 Tc
[(wit)-16(h)10.5(in)-333.9(6)-339.6(m)-1(onth)-16(s)10.8(,)-336.2(a)-1(nd)-333.9(a)-16(m)8.2(ong)-333.9(t)-16(h)10.5(ose,)-336.2(10)-339.6(pati)-16(e)9.3(n).2(ts)-333.7(a)-16(r)9.5(e)-335(e)-1(v)-16(e)9.4(n)-333.9(pre)-16(-)]TJ
0 -1.1174 TD
0 Tc
[(d)16.2(i)16.1(ct)25.3(e)15(d)-283.3(t)16.1(o)-289.1(r)16.2(e)15(c)15(o)16.2(ve)25.4(r)-283.3(t)16.1(he)-274.1(d)16.2(e)15(s)16.4(i)0(r)26.5(e)15(d)-283.3(C)15.2(D4)-273.8(l)16.1(e)15(v)16.2(e)0(l)-274.2(w)15.3(i)16.1(t)16.1(h)0(i)26.5(n)-283.3(3)-283.3(m)15(on)26.6(t)16.1(h)16.2(s)16.4(.)]TJ
1.0137 -1.1116 TD
[(Based)-302.4(on)-307.5(the)-304.1(identication)-306.3(of)-301.7(parameters)]TJ
/F8 1 Tf
17.0372 0 TD
(s)Tj
/F4 1 Tf
.6854 0 TD
(or)Tj
/F8 1 Tf
1.1347 0 TD
(A)Tj
/F4 1 Tf
.9216 0 TD
[(only,)-301.7(six)]TJ
-20.7925 -1.1116 TD
[(patients)-420.3(are)-414.5(declared)-422.5(to)-417(be)-412.3(critical:)-423(they)-414.6(are)-414.5(exactly)-420.4(those)]TJ
0 -1.1174 TD
[(for)-343.1(whom)]TJ
/F8 1 Tf
4.3486 0 TD
(t)Tj
/F4 1 Tf
7.3823 0 0 6.5614 107.6031 521.6313 Tm
(200)Tj
/F7 1 Tf
9.843 0 0 9.843 120.359 523.2755 Tm
(>)Tj
/F4 1 Tf
.72 0 TD
[(3)-340.9(months.)-339.5(Patients)-345.2(3,)-344.4(7,)-338.6(11,)-345.5(13,)-339.7(15,)-339.7(and)-344.3(16)]TJ
-6.6467 -1.1116 TD
[(were)-422.3(critical)-427.5(patients)-426(because)-426.9(they)-420.4(had)-424.9(the)-419.3(highest)-423.6(values)]TJ
T*
[(of)-267.1(apoptosis)-264.4(parameter)]TJ
/F8 1 Tf
9.4286 0 TD
(A)Tj
/F4 1 Tf
.8812 0 TD
[(and)-263.7(concurrently)-270.3(the)-263.8(lowest)-267.9(values)]TJ
-10.3099 -1.1174 TD
[(of)-359.3(the)-361.7(parameter)]TJ
/F8 1 Tf
7.1593 0 TD
(s.)Tj
/F4 1 Tf
.9964 0 TD
[(The)-357(immunological)-365.2(failure)-361.6(of)-359.3(patient)-361.8(3)]TJ
-8.1557 -1.1116 TD
[(was)-586.9(clinically)-591.1(conrmed)-588.2(after)-583.9(3)-582.8(months)-589.5(of)-583.9(monitoring.)]TJ
T*
[(Patient)-321.3(11)-313.2(was)-321.9(59)-313.2(years)-318.6(old)-320.2(at)-314.5(the)-321.4(time)-318.1(of)-313.2(the)-321.4(trial)-318(and)-315.5(was)]TJ
T*
[(the)-488.4(oldest)-485.9(among)-486(the)-488.4(16)-486(patients)-489.4(who)-488(were)-491.4(included.)-487.1(In)]TJ
0 -1.1174 TD
[(this)-367.3(special)-374.1(case,)-368.2(the)-373.2(small)-370.8(value)-370.8(of)]TJ
/F8 1 Tf
15.2114 0 TD
(s)Tj
/F4 1 Tf
.7545 0 TD
[(or)-365(the)-373.2(high)-367.4(value)-370.8(of)]TJ
/F8 1 Tf
-15.9659 -1.1116 TD
(A)Tj
/F4 1 Tf
1.0655 0 TD
[(rather)-446.7(indicated)-451.5(poor)-447.9(dynamics)-450(of)-451.4(the)-448.1(immune)-448.1(system,)]TJ
-1.0655 -1.1116 TD
[(which)-480(is)-485.9(standard)-483.3(at)-475.8(the)-482.6(age)-483.7(of)-480.2(60.)-477.9(Similar)-482.6(observations)]TJ
0 -1.1174 TD
[(were)-261(made)-255.6(for)-256.7(patient)-258.1(13)-255.6(who)-257.6(was)-258.6(49)-255.6(years)-261(old)-256.9(at)-256.9(the)-258(begin-)]TJ
0 -1.1116 TD
[(ning)-252.2(of)-255.6(the)-252.3(trial.)-252.4(The)-253.3(clinical)-254.7(monitoring)-254.5(of)-255.6(patient)-252.3(15)-249.9(shows)]TJ
T*
[(co-existing)-435.1(tuberculosis)-436(that)-432(weakened)-434.8(the)-430.8(immunological)]TJ
0 -1.1174 TD
[(system)-221.8(and)-217.6(explained)-226.8(the)-217.7(estimated)-222.2(values)-222(of)]TJ
/F8 1 Tf
18.1488 0 TD
(s)Tj
/F4 1 Tf
.599 0 TD
(and)Tj
/F8 1 Tf
1.6703 0 TD
(A)Tj
/F4 1 Tf
.6163 0 TD
[(.)-216.5(Patient)]TJ
-21.0344 -1.1116 TD
[(16)-307.5(was)-316.2(only)-309.8(18)-307.5(years)-312.9(old)-308.7(when)-311.7(he)-314.4(was)-310.4(enrolled)-310.9(in)-313.4(the)-309.9(trial.)]TJ
T*
[(He)-384.4(had)-384.6(a)-388.2(very)-385.7(low)-384.4(level)-388.2(of)-382.3(3)-387(CD4/mm)]TJ
7.3823 0 0 6.5614 223.8235 363.2881 Tm
(3)Tj
9.843 0 0 9.843 227.5086 358.9227 Tm
[(.)-389.3(This)-385.7(patient)-384.8(was)]TJ
-16.8126 -1.1116 TD
[(very)-558.5(young)-558.4(and)-557.4(his)-561.9(immunological)-561.1(system)-561.7(proved)-554.9(after)]TJ
0 -1.1174 TD
[(6)-306.4(m)15(on)15.1(th)20.7(s)-300.4(i)0(t)20.6(s)-306.2(ab)19.7(il)20.6(it)20.6(y)-306.4(t)0(o)-290.3(r)0(e)19.7(c)0(o)13.9(v)0(e)19.7(r)-300.6(fr)20.9(om)-297.2(it)20.6(s)-300.4(c)0(r)13.9(i)0(t)20.6(i)0(c)19.6(a)0(l)-291.5(s)0(t)15.1(a)0(t)19.6(u)0(s)21(.)]TJ
7.3823 0 0 6.5614 271.9558 341.348 Tm
-.0162 Tc
[(8,)-16.2(2)11.9(9)]TJ
/F8 1 Tf
9.843 0 0 9.843 287.5464 336.9826 Tm
0 Tc
(t)Tj
/F4 1 Tf
7.3823 0 0 6.5614 290.2109 335.3385 Tm
[(20)24.7(0)]TJ
9.843 0 0 9.843 62.022 326.0409 Tm
[(la)19.5(y)-467.6(w)0(i)14.1(t)0(h)20.7(i)0(n)-457.3(t)0(h)20.7(e)-468.8(ra)14(ng)20.8(e)-468.8(3)-467.6(mo)19.6(nt)20.7(hs)]TJ
/F7 1 Tf
13.0227 0 TD
(<)Tj
/F8 1 Tf
.7084 0 TD
(t)Tj
/F4 1 Tf
7.3823 0 0 6.5614 199.8425 324.3968 Tm
-.0162 Tc
[(20)-16.2(0)]TJ
/F7 1 Tf
9.843 0 0 9.843 212.2582 326.0409 Tm
0 Tc
(<)Tj
/F4 1 Tf
.7084 0 TD
-.0177 Tc
[(6)-485.3(m)-17.7(on)-17.7(th)-17.7(s)-474.7(\()-17.7(p)3.2(r)-17.7(ed)-17.7(ic)-17.7(te)-17.7(d)]TJ
-15.9717 -1.1116 TD
0 Tc
[(fr)20.9(om)-251.1(Eq)19.6(ua)19.7(ti)20.6(on)-249.9(4)-260.3(a)0(n)19.7(d)-260.3(ca)18.5(n)-260.3(b)0(e)-251(f)0(o)20.9(u)0(n)20.8(d)-260.3(in)-250(ta)19.6(bl)20.7(e)-261.4(1)-260.3(in)-250(re)19.7(fe)19.7(re)19.7(nc)19.7(e)-261.4(2)0(9)20.8(\))0(.)]TJ
1.0137 -1.1174 TD
[(The)-293.6(last)-287.9(column)-291.4(of)-290.2(the)-292.6(table)-296.1(2)-289.1(i)0(n)-290.3(Rivadeneira)-294.5(et)-291.5(al.)]TJ
7.3823 0 0 6.5614 276.0944 308.4661 Tm
(29)Tj
9.843 0 0 9.843 286.3558 304.1007 Tm
(dis-)Tj
-22.7912 -1.1116 TD
[(plays)-208.2(the)-206.2(immunological)-209.7(status)-209.2(of)-203.8(the)-211.9(patients)-207.2(after)-209.5(6)-202.7(months.)]TJ
T*
[(The)-259.1(latter)-257(was)-264.3(fully)-253.4(consistent)-261(with)-259(the)-258(previous)-257.5(results.)-259.8(The)]TJ
0 -1.1174 TD
[(11)-209.5(patients)-218.7(reaching)-214(the)-211.9(level)-215.4(200)-210.7(CD4/mm)]TJ
7.3823 0 0 6.5614 232.044 275.6409 Tm
(3)Tj
9.843 0 0 9.843 237.8267 271.2188 Tm
[(within)-209.5(6)-214.2(months)]TJ
-17.8608 -1.1116 TD
[(were)-261(all)-252.4(correctly)-261.3(identied,)-257.8(which)-255.3(suggests)-257.2(a)-255.7(good)-257.8(sensitiv-)]TJ
T*
[(ity)-326.1(of)-330.5(the)-327.1(measure)-334.7(based)-330.2(on)-330.5(the)-327.1(identied)-329.3(parameters)]TJ
/F8 1 Tf
22.1288 0 TD
(s)Tj
/F4 1 Tf
.7142 0 TD
(and)Tj
/F8 1 Tf
-22.843 -1.1174 TD
(A)Tj
/F4 1 Tf
.6163 0 TD
[(.)-446.9(The)-454.9(ve)-447.8(patients)-454.8(having)-451.4(a)-451.5(level)-451.6(below)-451.2(200)-452.6(CD4/mm)]TJ
7.3823 0 0 6.5614 297.4109 242.759 Tm
(3)Tj
9.843 0 0 9.843 62.022 227.3952 Tm
[(af)19.7(te)19.6(r)-300.6(6)-294.8(mo)19.6(nt)20.7(hs)-284.2(we)18.8(re)-285.6(co)19.7(rr)15.1(ec)18.5(tl)20.6(y)-294.8(i)0(d)20.7(e)0(n)19.7(t)0(i)14.8()0(e)19.8(d)-294.8(as)-285.4(we)18.8(ll)20.6(,)-297.2(w)0(h)20(i)0(c)19.6(h)-294.8(ag)19.7(ai)13.8(n)]TJ
0 -1.1116 TD
[(suggests)-228.4(a)-226.9(good)-223.3(specicity)-233.4(of)-226.8(the)-223.5(measure.)-228.7(These)-233.5(latter)-228.2(state-)]TJ
T*
[(ments)-376.5(deserve)-373.8(an)-372(exhaustive)-377.4(statistical)-378.9(study,)-371.7(which)-376.3(is)-370.8(be-)]TJ
0 -1.1174 TD
[(yond)-298.2(the)-304.1(scope)-301.4(of)-301.7(this)-304(review)-303.6(article.)]TJ
1.0137 -1.1116 TD
[(The)-259.1(conclusion)-261.1(of)-255.6(these)-261.2(results)-262.1(is)-255.6(that)-259.3(the)-263.8(identication)-260.2(of)]TJ
-1.0137 -1.1116 TD
[(the)-246.5(parameters)-247.2(in)-238.5(Equations)-248.5(13)-239.5(can)-247.5(be)-239.5(used)-247.3(for)-239.4(the)-246.5(early)-244.1(di-)]TJ
0 -1.1174 TD
[(agnosis)-394.5(of)-388.1(immunological)-394(failure)-390.4(just)-390.4(after)-393.8(the)-390.5(rst)-390(month)]TJ
0 -1.1116 TD
[(following)-408.6(initiation)-404.6(of)-405.3(a)-405.4(new)-408.5(therapy.)-405.2(The)-408.8(peculiarities)-411(of)]TJ
T*
[(each)-232.5(patient)-229.3(such)-224.2(as)-227.8(therapy)-229(adherence,)-232.2(age,)-233.7(or)-226.8(other)-225.6(circum-)]TJ
0 -1.1174 TD
[(stances)-264.4(must)-259(be)-262.5(taken)-261.4(into)-263.8(account)-264.8(by)-261.4(the)-258(physician)-265.7(to)-261.5(make)]TJ
0 -1.1116 TD
[(a)-301.8(nal)-299.3(clinical)-306.6(decision.)]TJ
/F1 1 Tf
8.9663 0 0 8.9663 62.022 95.4141 Tm
[(Prospective)-303.2(Research:)-298.9(Infection)-302.6(Control)]TJ
0 -1.2266 TD
[(and)-300.2(Drug)-305.7(Dosage)]TJ
/F4 1 Tf
9.843 0 0 9.843 72 67.9748 Tm
[(In)-365(the)-367.5(previous)-372.7(section,)-364.9(the)-367.5(parameters)-373.9(of)-365(a)-370.9(model)-365.1(were)]TJ
-1.0137 -1.1116 TD
[(identied)-507.8(for)-510.1(patients)-506.7(under)-507.7(treatment.)-513.8(In)-503.3(this)-511.3(section,)-508.9(a)]TJ
25.504 67.9184 TD
[(model)-342.1(for)-343.1(a)-336.3(patient)-344.5(without)-337.3(therapy)-344.2(will)-339.7(be)-337.4(considered)-342.7(and)]TJ
0 -1.1174 TD
[(used)-759.9(to)-751.1(review)-758.7(two)-753.1(special)-754.3(drug-scheduling)-756.1(therapies)]TJ
0 -1.1116 TD
[(design)-7.7(ed)-297.1(using)-304.9(control)-297.1(engineering)-309.6(methods.)]TJ
1.0137 -1.1116 TD
[(HIV)-661.6(drug-scheduling)-658.2(strategies)-665.3(have)-657.6(drawn)-658.4(attention)]TJ
-1.0137 -1.1116 TD
[(from)-408.7(the)-402(biomedical)-407.8(and)-407.6(control)-406.5(engineering)-407.5(communities)]TJ
0 -1.1174 TD
[(and)-378.8(many)-375.4(control)-383.5(strategies)-377.3(have)-381.1(been)-375.3(proposed)-378.4(for)-377.6(thera-)]TJ
0 -1.1116 TD
[(peutic)-412.4(treatment.)-415.8(For)-406.3(instance,)-413.2(state)-411.1(feedback)-416.6(and)-407.6(optimal)]TJ
T*
[(control)-544.8(of)-543.6(HIV)-546.4(infection)-548.2(have)-542.4(been)-542.4(explored)-546.9(in)-543.7(several)]TJ
0 -1.1174 TD
(works.)Tj
7.3823 0 0 6.5614 339.5338 642.2172 Tm
[(9,15,31)-10.4(36)]TJ
9.843 0 0 9.843 377.1779 637.8518 Tm
[(Howev)-8.4(er,)-444.5(most)-443.3(of)-445.7(these)-445.5(methods)-447.8(consider)]TJ
-6.5142 -1.1116 TD
[(the)-217.7(efcacy)-219.5(of)-215.3(the)-217.7(drugs)-212.6(as)-216.3(the)-217.7(control)-216.5(variable,)-217.6(which)-215(results)]TJ
T*
[(in)-296.1(strategies)-296.7(that)-293.8(are)-293.6(quite)-289.2(hard)-293.5(to)-290.3(use)-298(in)-290.3(practice)-295.9(since)-295.8(drug)]TJ
0 -1.1174 TD
[(efcacy)-340.5(is)-330.4(typically)-341.1(not)-331.7(expressed)-335.5(in)-336.4(terms)-336.1(of)-330.5(administered)]TJ
0 -1.1116 TD
[(drug)-419.1(amounts.)-422.4(To)-418.1(circumvent)-424.9(this)-419.2(drawback,)-419.8(pharmacoki-)]TJ
T*
[(netic)-319.1(and)-309.7(pharmacodynamic)-318.7(considerations)-318.4(can)-316.7(be)-308.6(included)]TJ
0 -1.1174 TD
[(in)-307.6(the)-304.1(model)-301.8(to)-301.8(relate)-309.8(efciency)-308.2(with)-299.3(drug)-303.9(dosage,)]TJ
7.3823 0 0 6.5614 515.5652 576.5101 Tm
(10)Tj
9.843 0 0 9.843 525.9401 572.088 Tm
[(as)-302.7(it)-302(is)]TJ
-21.6277 -1.1116 TD
[(shown)-317.2(next.)-320.2(Therapeutic)-317.7(treatments,)-324.6(designed)-316.3(using)-316.5(control)]TJ
T*
[(theory,)-403(are)-397.3(theoretical)-403.2(results)-400.4(with)-397.2(potential)-398.7(important)-398.6(im-)]TJ
T*
[(pact.)-482.6(The)-478(parameters)-483.3(used)-477.7(in)-474.6(the)-476.9(following)-477.7(models)-481.2(were)]TJ
0 -1.1174 TD
[(extracted)-239.4(from)-230.2(data)-237.2(available)-233.8(in)-232.7(the)-229.2(HIV)-235.4(literature)-233.8(and)-234.9(corre-)]TJ
0 -1.1116 TD
[(spond)-304.8(to)-301.8(an)-297.1(average)-306.1(patient)-304.2(not)-297.2(following)-304.9(any)-298.2(therapy.)]TJ
1.0137 -1.1116 TD
[(Antiretroviral)-468.4(therapy)-465.1(slows)-466.9(the)-465.4(clinical)-467.8(progression)-462.2(of)]TJ
-1.0137 -1.1174 TD
[(HIV)-500.3(infection)-502.2(at)-504.6(the)-494.2(beginning)-500.9(of)-503.3(the)-499.9(therapy.)-497.4(However)]TJ
0 -1.1116 TD
[(drug)-361.5(resistance)-366.8(due)-361.6(to)-353.7(viral)-364(mutation)-362.9(typically)-358.3(occurs)-365.8(after)]TJ
T*
[(some)-392.5(time)-393(and)-390.4(poses)-392.2(a)-388.2(challenging)-390.4(problem)-390.3(for)-394.9(long-term)]TJ
0 -1.1174 TD
[(treatments.)-480.1(Some)-478.9(studies)-475.3(have)-473.3(speculated)-476.5(that)-478.1(alternating)]TJ
0 -1.1116 TD
[(betwe)-8.8(en)-354.7(drug)-355.7(regimens)-357.9(on)-353.5(a)-353.6(xed)-356.8(schedule)-363.6(might)-352.6(forestall)]TJ
T*
[(therapeutic)-236(failure.)-238.3(Early)-232.6(stages)-233.3(of)-226.8(the)-235(virus)-230(evolution)-230.3(are)-230.2(as-)]TJ
0 -1.1174 TD
[(sumed)-347.5(to)-342.1(be)-337.4(mutation)-345.7(free.)-344.2(During)-341.6(further)-343(stages,)-346.2(the)-344.4(virus)]TJ
0 -1.1116 TD
[(mutation)-247.7(can)-241.8(no)-244.1(longer)-244(be)-245.3(ignored.)-242.8(This)-247.4(is)-238.3(considered)-250.6(for)-239.4(in-)]TJ
T*
[(stance)-349.9(in)-342.1(Hernandez-Vargas)-354.4(et)-343.3(al.,)]TJ
7.3823 0 0 6.5614 452.2393 412.1007 Tm
(37)Tj
9.843 0 0 9.843 463.0109 407.7353 Tm
[(in)-342.1(which)-341.7(the)-344.4(mutation)]TJ
-15.2344 -1.1116 TD
[(of)-342(the)-344.4(virus)-339.5(is)-342(modeled)-339.7(using)-339.5(switching)-346.2(systems,)-341.4(which)-341.7(in-)]TJ
0 -1.1174 TD
[(clude)-474.5(64)-474.5(virus)-472(strains)-469.5(and)-476.8(three)-474.5(drug)-470.9(combinations.)-475.4(This)]TJ
0 -1.1116 TD
[(issue)-305.9(remains)-304.9(the)-298.3(topic)-300.7(of)-301.7(ongoing)-301.6(research.)]TJ
1.0137 -1.1116 TD
[(In)-411.1(the)-413.5(results)-411.9(included)-408.8(in)-411.3(this)-413.4(review,)-410.8(the)-407.8(mathemati)-10.5(cal)]TJ
-1.0137 -1.1174 TD
[(models)-222(do)-215.3(not)-210.8(take)-220(into)-217.8(account)-218.7(drug)-211.7(resistance)-222.9(and)-217.6(mutation)]TJ
0 -1.1116 TD
[(of)-416.9(the)-413.5(virus.)-412(The)-414.6(drug)-407.6(therapies)-416.6(generated)-417.8(based)-416.6(on)-411.1(these)]TJ
T*
[(models)-325.7(were)-330.1(designed)-327.9(to)-324.9(act)-322.5(at)-326(the)-321.4(rst)-326.7(stages)-325.5(of)-324.7(the)-327.1(thera-)]TJ
0 -1.1174 TD
[(peutic)-360.5(regimen,)-360.4(during)-358(which)-359(the)-355.9(probability)-359.3(that)-357.2(the)-355.9(virus)]TJ
0 -1.1116 TD
[(devel)-8(ops)-412(some)-415.5(mutation)-414.8(is)-416.8(still)-414.8(low.)-410.9(Two)-420.1(control)-412.3(policies)]TJ
T*
[(are)-305.1(considered:)-303.6(feedback)-307.2(linearization)-307.6(and)-298.2(optimal)-304.2(control.)]TJ
/F13 1 Tf
8.9663 0 0 8.9663 313.0582 270.6519 Tm
[(Feedback)-305(linearization)-304.1(control)-299.9(applied)-300.6(to)-298.8(HIV)]TJ
0 -1.2203 TD
[(drug)-306.2(scheduling)]TJ
/F4 1 Tf
9.843 0 0 9.843 323.0361 243.2692 Tm
[(The)-293.6(problem)-292.4(of)-290.1(drug)-292.4(administration)-295.9(is)-295.9(classically)-293.4(divided)]TJ
-1.0137 -1.1174 TD
[(into)-240.8(two)-234.7(phases:)-240.2(a)-232.6(so-called)-243.8(pharmacodynamic)-238(phase)-238(that)-236.2(re-)]TJ
0 -1.1116 TD
[(lates)-370.8(the)-373.2(concentration)-370.7(of)-365(drugs)-368.1(at)-372.1(the)-367.5(site)-368.5(of)-365(action)-372.1(to)-365.2(the)]TJ
T*
[(magnitude)-365.1(of)-359.3(the)-361.7(effect)-367.3(produced,)-360.1(modeled)-362.7(as)]TJ
/F11 1 Tf
19.3872 0 TD
(g)Tj
/F7 1 Tf
.8352 0 TD
(=)Tj
ET
520.838 212.655 28.857 .39687 re
f
BT
/F8 1 Tf
6.8899 0 0 6.8899 529.6251 214.5826 Tm
(w)Tj
/F4 1 Tf
.6665 0 TD
(\()Tj
/F8 1 Tf
.3374 0 TD
(t)Tj
/F4 1 Tf
.2962 0 TD
(\))Tj
/F8 1 Tf
-2.5755 -1.1026 TD
(w)Tj
/F4 1 Tf
.6665 0 TD
(\()Tj
/F8 1 Tf
.3291 0 TD
(t)Tj
/F4 1 Tf
.3045 0 TD
(\))Tj
/F10 1 Tf
.5019 0 TD
()Tj
/F8 1 Tf
.938 0 TD
(w)Tj
/F4 1 Tf
4.9215 0 0 4.9215 544.3085 205.9653 Tm
(50)Tj
9.843 0 0 9.843 549.6943 210.3874 Tm
(,)Tj
-24.041 -1.1174 TD
[(and)-424.9(a)-417(pharmacokinetic)-427.1(phase)-422.3(that)-420.5(relates)-425.9(dose,)-417.7(frequency,)]TJ
0 -1.1116 TD
[(and)-557.4(route)-553.9(of)-555.1(administration)-555.1(to)-555.3(drug)-551.5(leveltime)-557.7(relation-)]TJ
T*
[(ships)-310.5(in)-313.4(the)-309.9(body,)-307.3(mathematically)-318.1(described)-312.8(as)]TJ
/F9 1 Tf
19.5657 .0058 TD
(_)Tj
/F8 1 Tf
-.2016 -.0058 TD
(w)Tj
/F7 1 Tf
.8352 0 TD
(=)Tj
/F10 1 Tf
.72 0 TD
()Tj
/F8 1 Tf
.9388 0 TD
(Kw)Tj
/F10 1 Tf
1.4975 0 TD
()Tj
/F8 1 Tf
-23.3556 -1.1174 TD
(u)Tj
/F4 1 Tf
.5011 0 TD
(\()Tj
/F8 1 Tf
.3341 0 TD
(t)Tj
/F4 1 Tf
.3053 0 TD
(\))Tj
/F11 1 Tf
.3283 0 TD
(d)Tj
/F4 1 Tf
.5011 0 TD
(\()Tj
/F8 1 Tf
.3341 0 TD
(t)Tj
/F10 1 Tf
.4665 0 TD
()Tj
/F11 1 Tf
.9388 0 TD
(s)Tj
/F8 1 Tf
6.8899 0 0 6.8899 353.8771 165.033 Tm
(k)Tj
/F4 1 Tf
9.843 0 0 9.843 357.6188 166.507 Tm
[(\).)-568.9(The)-570.1(parameter)]TJ
/F8 1 Tf
7.8735 0 TD
(w)Tj
/F4 1 Tf
7.3823 0 0 6.5614 441.6944 164.9196 Tm
(50)Tj
9.843 0 0 9.843 454.6771 166.507 Tm
[(is)-572.3(the)-569(concentration)-572.3(of)]TJ
-14.3877 -1.1116 TD
[(drug)-298.1(that)-299.6(lowers)-296.5(the)-298.3(viral)-294.9(load)-299.4(by)-290.2(50%,)]TJ
/F8 1 Tf
16.2596 0 TD
(K)Tj
/F4 1 Tf
.9619 0 TD
[(is)-295.9(the)-298.3(elimination)]TJ
-17.2215 -1.1116 TD
[(rate)-214.2(constant)-218.6(of)-209.5(the)-211.9(drug,)]TJ
/F8 1 Tf
10.0564 0 TD
(u)Tj
/F4 1 Tf
.5011 0 TD
(\()Tj
/F8 1 Tf
.3341 0 TD
(t)Tj
/F4 1 Tf
.2822 0 TD
[(\))-208.4(i)0(s)-215.2(the)-211.9(amount)-210.7(of)-215.3(drug)-206(expressed)]TJ
-11.1738 -1.1116 TD
[(in)-347.9(milligrams,)-346.7(and)]TJ
/F12 1 Tf
7.8678 0 TD
(s)Tj
/F8 1 Tf
7.3823 0 0 6.5614 394.8094 132.0378 Tm
(k)Tj
/F4 1 Tf
9.843 0 0 9.843 401.4991 133.6818 Tm
[(is)-347.7(the)-344.4(time)-346.9(at)-343.3(which)-347.5(the)-344.4(patient)-350.2(takes)]TJ
-8.9851 -1.1174 TD
[(the)-304.1(drug.)]TJ
1.0137 -1.1116 TD
[(Pharmacokinetic)-363.6(and)-355.8(pharmacodynamic)-364.7(drug)-355.7(parameters)]TJ
-1.0137 -1.1116 TD
[(are)-408.8(usually)-406.4(evaluated)]TJ
/F8 1 Tf
9.1983 0 TD
[(in)-405.5(vitro)]TJ
/F4 1 Tf
3.0814 0 TD
[(,)-400.8(whereas)]TJ
/F8 1 Tf
4.3371 0 TD
[(in)-405.5(vivo)]TJ
/F4 1 Tf
3.2715 0 TD
(parameters)Tj
-19.8883 -1.1174 TD
[(are)-564.3(needed.)-560.7(Pharmacological)-565.2(characteristics)-570.7(of)-555.1(any)-563.2(drug)]TJ
0 -1.1116 TD
[(vary)-345.4(signicantly)-344(when)-340.5(evaluated)]TJ
/F8 1 Tf
14.1228 0 TD
[(in)-342.1(vitro)]TJ
/F4 1 Tf
3.3579 0 TD
(or)Tj
/F8 1 Tf
1.175 0 TD
[(in)-336.4(vivo)]TJ
/F4 1 Tf
2.7992 0 TD
[(.)-337.5(Thus,)]TJ
-21.4549 -1.1116 TD
(the)Tj
/F8 1 Tf
1.6415 0 TD
[(in)-411.3(vivo)]TJ
/F4 1 Tf
3.2773 0 TD
[(parameters)-420(given)-410(by)-411.1(Legrand)-408.6(et)-412.4(al.)]TJ
7.3823 0 0 6.5614 506.5511 72.2834 Tm
(38)Tj
9.843 0 0 9.843 518.0031 67.9181 Tm
[(are)-408.8(used)]TJ
-20.8213 -1.1174 TD
[(herein.)-306.2(The)-299.4(model)-301.8(used)-304.9(is)-301.6(as)-296.9(follows:)]TJ
/F1 1 Tf
8.9663 0 0 8.9663 62.022 749.5368 Tm
(236)Tj
44.2983 0 TD
[(RIVADENEIRA)-308.5(ET)-300.7(AL.)]TJ
ET
endstream
endobj
79 0 obj
<>/ProcSet [/PDF /Text /ImageB /ImageC /ImageI]/XObject<>/Font<>>>/Thumb 82 0 R/MediaBox[0 0 612 792]/Rotate 0>>
endobj
83 0 obj
<>/ProcSet[/PDF/Text/ImageB]/XObject<>/Font<>>>
endobj
80 0 obj
<>stream
/GS1 gs
BT
/F9 1 Tf
9.843 0 0 9.843 151.4267 725.4423 Tm
0 0 0 rg
0 Tc
0 Tw
(_)Tj
/F8 1 Tf
-.1843 -.2131 TD
(T)Tj
/F7 1 Tf
.8006 0 TD
(=)Tj
/F8 1 Tf
.72 0 TD
(s)Tj
/F10 1 Tf
.5529 0 TD
()Tj
/F11 1 Tf
.9388 0 TD
(d)Tj
/F8 1 Tf
.4953 0 TD
(T)Tj
/F10 1 Tf
.8006 0 TD
()Tj
/F11 1 Tf
.9388 0 TD
(b)Tj
/F8 1 Tf
.5529 0 TD
(TV)Tj
/F4 1 Tf
8.1961 0 TD
(\(5\))Tj
/F9 1 Tf
-14.0018 -2.4133 TD
(_)Tj
/F8 1 Tf
-.1843 -.2131 TD
(T)Tj
/F10 1 Tf
6.8899 0 0 6.8899 154.0346 701.5746 Tm
()Tj
/F7 1 Tf
9.843 0 0 9.843 159.5905 697.4927 Tm
(=)Tj
/F11 1 Tf
.72 0 TD
(b)Tj
/F8 1 Tf
.5529 0 TD
(TV)Tj
/F10 1 Tf
1.4111 0 TD
()Tj
/F11 1 Tf
.9388 0 TD
(l)Tj
/F8 1 Tf
.5529 0 TD
(T)Tj
/F10 1 Tf
6.8899 0 0 6.8899 206.9291 701.5746 Tm
()Tj
/F4 1 Tf
9.843 0 0 9.843 287.3763 697.4927 Tm
(\(6\))Tj
/F9 1 Tf
-16.6283 -2.9778 TD
(_)Tj
/F8 1 Tf
-.2131 -.2131 TD
(V)Tj
/F7 1 Tf
.864 0 TD
(=)Tj
/F4 1 Tf
1.4457 0 TD
(1)Tj
/F10 1 Tf
.6681 0 TD
()Tj
ET
161.745 668.353 31.408 .39685 re
f
BT
/F8 1 Tf
9.843 0 0 9.843 174.1606 672.7747 Tm
(w)Tj
-1.2614 -1.3651 TD
(w)Tj
/F10 1 Tf
.8352 0 TD
()Tj
/F8 1 Tf
.9388 0 TD
(w)Tj
/F4 1 Tf
6.8899 0 0 6.8899 185.7826 657.8644 Tm
(50)Tj
/F16 1 Tf
9.843 0 0 9.843 137.1401 679.9746 Tm
4.9616 Tc
()Tj
/F8 1 Tf
6.4221 -1.4111 TD
0 Tc
(kT)Tj
/F10 1 Tf
6.8899 0 0 6.8899 211.011 670.1667 Tm
()Tj
9.843 0 0 9.843 216.5669 666.0848 Tm
()Tj
/F8 1 Tf
.9388 0 TD
(cV)Tj
/F4 1 Tf
6.255 0 TD
(\(7\))Tj
/F9 1 Tf
-15.7701 -3.1851 TD
(_)Tj
/F8 1 Tf
-.1958 -.0058 TD
(w)Tj
/F7 1 Tf
.8294 0 TD
(=)Tj
/F10 1 Tf
.72 0 TD
()Tj
/F8 1 Tf
.9388 0 TD
(Kw)Tj
/F10 1 Tf
1.4975 0 TD
()Tj
/F8 1 Tf
.9388 0 TD
(u)Tj
/F4 1 Tf
.5011 0 TD
(\()Tj
/F8 1 Tf
.3341 0 TD
(t)Tj
/F4 1 Tf
.2995 0 TD
(\))Tj
/F11 1 Tf
.3341 0 TD
(d)Tj
/F4 1 Tf
.5011 0 TD
(\(1)Tj
/F10 1 Tf
.9964 0 TD
()Tj
/F11 1 Tf
.9388 0 TD
(s)Tj
/F8 1 Tf
6.8899 0 0 6.8899 221.4424 633.203 Tm
(k)Tj
/F4 1 Tf
9.843 0 0 9.843 225.1842 634.677 Tm
[(\))-5985.4(\(8\))]TJ
-16.8068 -1.8373 TD
[(The)-305.2(control)-302.8(strategy)-299.2(is)-301.6(computed)-306.2(taking)-301.8(into)-298.4(account)-305.1(that)]TJ
1.2729 -1.7164 TD
[(i.)-505.8(The)-201.5(effect)-206(of)-198(antiretroviral)-209.5(drugs)-201.1(has)-200.1(a)-203.8(strong)-202.3(impact)-200.5(on)]TJ
1.0367 -1.1174 TD
[(the)-229.2(value)-232.6(of)-232.6(the)-235(parameter)]TJ
/F8 1 Tf
10.6439 0 TD
(k)Tj
/F4 1 Tf
.6796 0 TD
(\(therefore)Tj
/F12 1 Tf
4.1931 0 TD
(g)Tj
/F4 1 Tf
7.3823 0 0 6.5614 240.1511 587.1116 Tm
(1)Tj
9.843 0 0 9.843 246.1039 588.6991 Tm
[(is)-232.5(assumed)-235.5(to)]TJ
-16.6225 -1.1116 TD
[(be)-297.1(zero\))-301.5(as)-302.7(is)-301.6(explained)-307.4(in)-296.1(Mhawej)-304.6(et)-303(al.)]TJ
7.3823 0 0 6.5614 245.7637 582.1227 Tm
(39)Tj
9.843 0 0 9.843 69.6189 566.8156 Tm
[(ii.)-501.2(A)-249.6(discrete)-248.5(drug)-252(trajectory)]TJ
/F8 1 Tf
11.8362 0 TD
(u)Tj
/F4 1 Tf
.5011 0 TD
(\()Tj
/F8 1 Tf
.3341 0 TD
(t)Tj
/F4 1 Tf
.2822 0 TD
[(\))-243(i)0(s)-249.8(derived)-252(by)-244.1(mean)-8(s)-242.8(o)0(f)-249.8(a)]TJ
-11.6404 -1.1116 TD
[(nonlinear)-346.5(control)-348.9(strategy)-345.2(such)-351(as)-343(feedback)-353.3(lineariza-)]TJ
0 -1.1174 TD
[(tion)-298.4(for)-302.7(impulsive)-300.5(control)-302.8(systems.)]TJ
7.3823 0 0 6.5614 221.8393 549.2408 Tm
(11)Tj
9.843 0 0 9.843 69.7323 528.4345 Tm
[(Based)-843.8(on)-837.4(these)-842.9(aforementioned)-845.1(considerations,)-840.2(the)]TJ
-1.0137 -1.1116 TD
[(amount)-291.4(of)-284.4(drug)-286.6(really)-291.4(present)-286.4(in)-290.3(the)-286.8(body)-286.6(can)-287.9(be)-285.6(computed.)]TJ
T*
[(A)-364.8(full)-356(description)-365.9(of)-359.3(the)-361.7(technique)-365(is)-359.2(provided)-361.4(by)-359.3(Mhawej)]TJ
0 -1.1174 TD
[(et)-303(al.)]TJ
7.3823 0 0 6.5614 79.5401 499.9747 Tm
(10)Tj
9.843 0 0 9.843 89.9149 495.5526 Tm
[(and)-298.2(Rivadeneira)-306(et)-303(al.)]TJ
7.3823 0 0 6.5614 177.6189 499.9747 Tm
(11)Tj
9.843 0 0 9.843 69.7323 484.6109 Tm
[(This)-241.7(setup)-237(based)-243.8(on)-232.6(impulsive)-242.9(control)-239.5(systems)-240(allows)-244.9(var-)]TJ
-1.0137 -1.1116 TD
[(iations)-452.6(of)-451.4(the)-453.8(control)-452.6(variable)-450.3(in)-451.6(amounts)-453.5(of)-445.7(drug)-453.6(\(milli-)]TJ
0 -1.1174 TD
[(grams\))-337(instead)-338.4(of)-336.2(in)-330.6(terms)-341.9(of)-330.5(their)-335.2(efciency)-342.8(and)-332.8(describes)]TJ
0 -1.1116 TD
[(in)-301.8(a)-301.8(realistic)-307.4(way)-299.1(how)-303.7(the)-298.3(patient)-304.2(follows)-302.4(the)-304.1(therapy.)]TJ
1.0137 -1.1116 TD
[(Some)-530.8(results)-527.1(of)-526.3(this)-528.6(control)-527.5(method)-533.3(are)-524(illustrated)-533.2(in)]TJ
-1.0137 -1.1116 TD
[(Fig.)-283.2(2,)-275.2(which)-284.1(represents)-279.1(the)-281.1(infection)-283.3(evolution)-282.2(for)-273.9(different)]TJ
0 -1.1174 TD
[(values)-256.5(of)-249.8(the)-252.3(dosing)-248.4(interval)]TJ
/F12 1 Tf
11.6231 0 TD
(s)Tj
/F8 1 Tf
7.3823 0 0 6.5614 178.4692 417.203 Tm
(k)Tj
/F4 1 Tf
9.843 0 0 9.843 181.7574 418.8471 Tm
[(.)-251.1(The)-253.3(simulation)-249.9(is)-255.6(performed)]TJ
-12.3949 -1.1116 TD
[(when)-288.7(zidovudine)-290.1(\(ZDV\))-284.9(is)-290.1(given)-283.3(twice)-291.2(a)-284.5(day)-286.7(\()]TJ
/F12 1 Tf
18.9322 0 TD
(s)Tj
/F8 1 Tf
7.3823 0 0 6.5614 250.4125 406.2613 Tm
(k)Tj
/F7 1 Tf
9.843 0 0 9.843 255.3448 407.9054 Tm
(=)Tj
/F4 1 Tf
.72 0 TD
[(0.5)-287.9(days\))]TJ
-20.591 -1.1116 TD
[(following)-425.8(the)-425.1(closed-loop)-423.4(control)-423.8(strategy.)-423.5(In)-422.6(Fig.)-421.4(2a,)-421.5(the)]TJ
0 -1.1174 TD
[(virus)-500.7(load)-501(approaches)-505(the)-499.9(desired)-505.3(healthy)-499.9(equilibrium)-504.6(in)]TJ
0 -1.1116 TD
[(the)-459.6(expected)-462.9(time,)-459.7(according)-462.8(to)-457.3(the)-459.6(requirement)-466.3(to)-457.3(reach)]TJ
T*
[(200)-343.1(cells/mm)]TJ
7.3823 0 0 6.5614 114.2362 368.4471 Tm
(3)Tj
9.843 0 0 9.843 121.3228 364.0818 Tm
[(within)-341.9(6)-346.7(months.)-345.3(In)-342(Fig.)-340.8(2b,)-345.5(a)-342.1(discrete)-352.1(time)]TJ
-6.255 -1.1174 TD
[(scheduling)-307.2(of)-301.7(the)-298.3(antiretroviral)-307.4(drug)-298.1(can)-305.1(be)-297.1(seen.)]TJ
1.0137 -1.1116 TD
[(As)-233.3(we)-234.6(can)-230.3(see,)-233.5(the)-235(inclusion)-230.1(of)-232.6(pharmacokinetic)-237(and)-234.9(phar-)]TJ
-1.0137 -1.1116 TD
[(macodynamic)-393.8(models)-389.1(using)]TJ
/F8 1 Tf
11.865 0 TD
[(in)-388.2(vivo)]TJ
/F4 1 Tf
3.237 0 TD
[(parameters)-391.1(along)-392.7(with)]TJ
-15.1019 -1.1174 TD
[(impulsive)-409.9(control)-406.5(becomes)-409.7(a)-411.2(valuable)-410(tool)-402.1(to)-405.5(test)-408.8(and)-407.6(de-)]TJ
0 -1.1116 TD
[(sign)-246.2(therapeutical)-256.8(strategies.)-248.3(Note)-248.5(that)-247.7(this)-246.4(result)-249.7(is)-244(observed)]TJ
T*
[(when)-513.3(considering)-515.6(a)-509.1(ZDV)-513.1(monotherapy.)-514.5(More)-507.5(signicant)]TJ
T*
[(results)-417.6(could)-415.7(be)-418.1(obtained)-414.6(with)-414.5(multithera)-9.3(pies.)-412.1(Discussions)]TJ
0 -1.1174 TD
[(about)-242.9(the)-240.7(use)-240.4(of)-238.3(multitherapies)-245.2(or)-244.1(the)-235(conve)-7.8(nience)-240.6(of)-238.3(admin-)]TJ
0 -1.1116 TD
[(istering)-206(the)-200.4(drug)-200.2(once,)-206(twice,)-202.5(or)-198(three)-203.8(times)-203.8(per)-200.3(day;)-201.5(that)-201.7(is,)-201.4(to)]TJ
T*
[(consider)-293.3(drug)-292.4(impulses)-293.3(at)-285.7(variable)-294.8(times)]TJ
/F12 1 Tf
16.6743 0 TD
(s)Tj
/F8 1 Tf
7.3823 0 0 6.5614 228.1889 252.8503 Tm
(k)Tj
/F4 1 Tf
9.843 0 0 9.843 234.3684 254.4944 Tm
[(are)-287.8(left)-293.8(open)-287.8(for)]TJ
-17.7399 -1.1174 TD
[(future)-301.6(works.)]TJ
1.0137 -1.1116 TD
[(One)-391.2(major)-388.1(advantage)-389.1(of)-388.1(the)-384.7(control)-389.2(schemes)-392.2(cited)-388.2(\(like)]TJ
-1.0137 -1.1116 TD
[(state)-307.4(feedback\))-308.3(is)-301.6(their)-300.6(ability)-303.1(to)-301.8(minimize)-307.7(the)-304.1(viral)-300.6(load)-305.2(by)]TJ
0 -1.1174 TD
[(means)-222(of)-221(a)-221.1(time-varying)-224.5(administration)-226.8(strategy)-224.3(aimed)-222.3(at)-216.6(op-)]TJ
0 -1.1116 TD
[(timally)-275.6(adjusting)-270.5(the)-275.3(efciency)-273.7(of)-272.9(the)-269.5(drugs)-270.2(to)-273(the)-269.5(dynamics)]TJ
T*
[(of)-255.6(the)-252.3(patient.)-255.8(This)-253.2(means)-250.8(that)-253.5(if)-255.7(the)-252.3(efciency)-256.4(of)-249.8(the)-252.3(drug)-252(is)]TJ
T*
[(related)-351.2(to)-347.9(its)-348.9(dosage,)-352(no)-347.8(full)-344.5(dosage)-354.3(is)-347.7(needed)-349.9(all)-344.5(the)-350.2(time.)]TJ
0 -1.1174 TD
[(The)-362.8(benets)-361.2(appear)-361.4(through)-359.2(a)-359.4(reduction)-363.8(of)-359.3(the)-355.9(side)-362.6(effects)]TJ
0 -1.1116 TD
[(caused)-303.6(by)-301.7(the)-304.1(use)-298(of)-301.7(dynamically)-305.2(nonoptimal)-301.8(drug)-303.9(doses.)]TJ
/F13 1 Tf
8.9663 0 0 8.9663 59.7543 128.1259 Tm
[(Control)-303.2(of)-298.8(HIV)-301.4(infection)-302.7(with)-304.9(minimum)-298.5(side)-302.5(effects)]TJ
/F4 1 Tf
9.843 0 0 9.843 69.7323 111.685 Tm
[(In)-313.2(Costanza)-312.8(et)-308.8(al.,)]TJ
7.3823 0 0 6.5614 142.5826 116.107 Tm
(9)Tj
9.843 0 0 9.843 149.3291 111.685 Tm
[(extended)-311.9(dynamics)-311.8(of)-307.4(the)-315.6(HIV)-310.3(infec-)]TJ
-9.1003 -1.1116 TD
[(tion)-511.5(model)-514.9(were)-514.4(developed.)-518.1(A)-508.8(new)-512.2(differential)-518.2(equation)]TJ
T*
[(was)-442.9(included)-443.4(to)-434.3(model)-440(the)-442.3(generation)-441(of)-439.9(side)-437.5(effects)-443(due)]TJ
0 -1.1174 TD
[(to)-284.6(medication.)-284.5(After)-289.8(that,)-280(optimal)-287(control)-285.6(theory)-284.3(was)-281.6(imple-)]TJ
0 -1.1116 TD
[(mented)-419.2(to)-417(minimize)-422.9(side)-414.4(effects.)-423.4(This)-414.5(subsection)-422.2(resumes)]TJ
T*
[(those)-432.8(main)-427.4(results.)-432.6(Side)-431.8(effects)-431.5(appear)-430.5(and)-430.7(evolve)-429.5(during)]TJ
25.5097 22.8833 TD
[(the)-258(therapy)-257.8(process,)-260.7(frequently)-261.2(persisting)-259.8(even)-260.2(if)-255.7(medication)]TJ
0 -1.1116 TD
[(is)-232.5(discontinued.)-232.3(Since)-232.4(the)-235(characteristics)-242.4(of)-232.6(these)-232.4(side)-230.1(effects)]TJ
0 -1.1174 TD
[(have)-363.8(a)-359.4(wide)-369.4(range,)-362.6(it)-359.6(is)-365(virtually)-362.9(impossible)-370.5(to)-359.4(identify)-367.4(all)]TJ
0 -1.1116 TD
[(disorders)-408.2(provoked)-407.4(by)-411.1(medication)-407.8(in)-411.3(a)-405.4(patient,)-411.3(and)-407.6(some-)]TJ
T*
[(times)-491.8(it)-497.8(is)-491.7(difcult)-494(to)-491.9(conrm)-498.4(that)-489.6(an)-498.7(eventually)-493(arising)]TJ
T*
[(disease,)-204.4(different)-208.2(from)-201.4(HIV,)-204.3(is)-203.7(a)-198.1(side)-207.1(effect.)-203.7(However,)-205.3(a)-203.8(com-)]TJ
0 -1.1174 TD
[(parison)-268(study)-270.4(on)-267.1(efcacy)-271.4(and)-269.4(side)-270.4(effects)-276(for)-268.2(different)-271.6(doses)]TJ
0 -1.1116 TD
[(of)-342(ZDV)-340.3(has)-344.1(shown)-340.2(that)-339.9(the)-344.4(incidence)-343.1(of)-342(some)-340.7(moderate)-347.7(to)]TJ
T*
[(severe)-303.6(side)-299.2(effects)-304.8(was)-304.6(dose)-299.1(related.)]TJ
7.3823 0 0 6.5614 455.8109 198.8787 Tm
[(40,)-9.4(41)]TJ
9.843 0 0 9.843 320.8251 183.5149 Tm
[(Using)-288.5(t)16.1(h)0(e)-262.5(p)16.2(er)25.5(c)15(e)15(n)16.2(t)16.1(a)0(g)25.4(e)15(s)-277.4(o)16.2(f)-277.5(p)16.2(a)15(t)16(i)16.1(e)15(nt)26.5(s)-277.4(a)15(f)16.2(f)16.2(e)15(ct)25.3(e)15(d)-277.6(b)16.2(y)-271.8(th)26.5(e)15(s)16.4(e)-278.7(s)16.4(i)16(d)16.2(e)-278.7(e)15(f)16.2(-)]TJ
-1.0137 -1.1116 TD
-.0156 Tc
[(fect)-15.6(s)-202(i).4(n)-218.3(t).5(he)-213.7(me)-15.6(d)9.8(i).5(an)-218.3(follo)-15.6(w)10.1(-up)-218.3(perio)-15.6(d)-202.1(as)-218.1(a)-213.7(r).6(ef)-15.6(e)9.9(r).6(enc)-15.6(e)8.7(,)-214.9(a)-.6(n)-212.5(e)-.6(s)-15.6(t)11.1(imat)-15.6(e)]TJ
T*
-.0159 Tc
[(of)-241.6(th)-15.9(e)-232.4(pro)-15.9(b)10.7(a)-.9(bili)-15.9(t)10.4(y)-241.6(th)-15.9(a)9.5(t)-241.8(HIV)-248.3(p).3(atie)-15.9(n)9.5(t).2(s)-241.4(p).3(r)-15.9(e)9.6(sent)-247.5(any)-241.6(c)-15.9(o)9.5(n).3(rme)-15.9(d)-232.4(s).5(id)-15.9(e)]TJ
0 -1.1174 TD
-.0157 Tc
[(effe)-15.7(c)8.6(t)-247.3(up)-252.9(to)-247.2(a)-254.1(g).5(iven)-252.9(time)-254.1(a)-.7(fter)-252.9(the)-254.1(b).5(egin)-15.7(n)10.9(i).3(ng)-252.9(of)-247.2(med)-15.7(i)10.8(cati)-15.7(o)10.8(n)-247.2(can)]TJ
0 -1.1116 TD
-.0159 Tc
[(be)-358(compu)-15.9(t)10.6(ed.)-359.2(I).3(n)-356.8(t).2(he)-358(s)-15.9(a)9.7(me)-358(line)-358(o).3(f)-356.8(r)-15.9(e)9.6(a)-.9(son)-15.9(i)10.6(ng,)-359.1(these)-358(d)-15.9(a)9.5(t).2(a)-358(w)-.6(ere)]TJ
T*
[(used)-512.3(to)-506.6(d)-15.9(e)9.5(scri)-15.9(b)10.6(e)-507.7(\(a)-15.9(p)9.5(prox)-15.9(i)10.6(matel)-15.9(y)10.6(\))-506.5(th)-15.9(e)-497.3(dyn)-15.9(a)9.5(m)-.9(ic)-507.7(be)-15.9(h)9.5(a)-.9(vio)-15.9(r)-496.1(of)]TJ
T*
[(such)-305.1(a)-300.5(pro)-16(b)10.6(a)-1(bili)-16(t)10.3(y)]TJ
/F8 1 Tf
7.3436 0 TD
0 Tc
(p)Tj
/F4 1 Tf
.4838 0 TD
(\()Tj
/F8 1 Tf
.3225 0 TD
(t)Tj
/F4 1 Tf
.2649 0 TD
-.016 Tc
[(\))-299.3(t).1(h)-16(r)10.6(ough)-305.1(an)-299.3(equ)-16(a)9.4(tion)-305.1(of)-299.3(the)-306.2(form)]TJ
7.3823 0 0 6.5614 524.1259 122.1732 Tm
-.0171 Tc
(9.32)Tj
9.843 0 0 9.843 536.4849 117.8078 Tm
0 Tc
(:)Tj
/F9 1 Tf
-21.9042 -1.9065 TD
(_)Tj
/F8 1 Tf
-.1152 -.0058 TD
(p)Tj
/F7 1 Tf
.6681 0 TD
(=)Tj
/F4 1 Tf
.72 0 TD
(\()Tj
/F8 1 Tf
.3341 0 TD
(d)Tj
/F4 1 Tf
6.8899 0 0 6.8899 341.5747 97.5118 Tm
(0)Tj
/F10 1 Tf
9.843 0 0 9.843 347.1873 98.9858 Tm
()Tj
/F8 1 Tf
.9388 0 TD
(d)Tj
/F4 1 Tf
6.8899 0 0 6.8899 361.3038 97.5118 Tm
(1)Tj
/F8 1 Tf
9.843 0 0 9.843 365.2723 98.9858 Tm
(u)Tj
/F10 1 Tf
.6681 0 TD
()Tj
/F8 1 Tf
.9388 0 TD
(d)Tj
/F4 1 Tf
6.8899 0 0 6.8899 385.9652 97.5118 Tm
(2)Tj
/F8 1 Tf
9.843 0 0 9.843 389.9338 98.9858 Tm
(u)Tj
/F4 1 Tf
6.8899 0 0 6.8899 394.866 103.0677 Tm
(2)Tj
/F10 1 Tf
9.843 0 0 9.843 400.4219 98.9858 Tm
()Tj
/F8 1 Tf
.9388 0 TD
(d)Tj
/F4 1 Tf
6.8899 0 0 6.8899 414.5952 97.5118 Tm
(3)Tj
/F8 1 Tf
9.843 0 0 9.843 418.507 98.9858 Tm
(u)Tj
/F4 1 Tf
6.8899 0 0 6.8899 423.4393 103.0677 Tm
(3)Tj
9.843 0 0 9.843 427.4077 98.9858 Tm
(\))Tj
/F8 1 Tf
.3341 0 TD
(p)Tj
/F4 1 Tf
.5011 0 TD
(\(1)Tj
/F10 1 Tf
.9964 0 TD
()Tj
/F8 1 Tf
.9388 0 TD
(p)Tj
/F4 1 Tf
.5011 0 TD
(\)\()Tj
/F8 1 Tf
.6681 0 TD
(V)Tj
/F10 1 Tf
.8582 0 TD
()Tj
/F8 1 Tf
.9388 0 TD
(V)Tj
6.8899 0 0 6.8899 489.94 97.5118 Tm
(h)Tj
/F4 1 Tf
9.843 0 0 9.843 493.8519 98.9858 Tm
(\))Tj
/F8 1 Tf
6.8899 0 0 6.8899 497.14 103.0677 Tm
(w)Tj
/F4 1 Tf
9.843 0 0 9.843 502.2424 98.9858 Tm
(,)Tj
/F8 1 Tf
.4205 0 TD
(p)Tj
/F4 1 Tf
.4953 0 TD
(\(0\))Tj
/F7 1 Tf
1.3363 0 TD
(=)Tj
/F8 1 Tf
.72 0 TD
(p)Tj
/F4 1 Tf
6.8899 0 0 6.8899 536.3715 97.5118 Tm
(0)Tj
/F14 1 Tf
9.843 0 0 9.843 540.34 98.9858 Tm
(:)Tj
/F4 1 Tf
-.1901 -1.4111 TD
(\(9\))Tj
-22.1115 -1.751 TD
[(Several)-287.6(considerations)-289.6(based)-289.9(on)-284.4(the)-286.8(structure)-288.7(of)-284.4(Equation)]TJ
-1.0137 -1.1174 TD
[(9)-300.6(need)-300.5(to)-301.8(be)-297.1(taken)-307.5(into)-298.4(consideration)-306(at)-303(this)-298.2(stage:)]TJ
ET
q
238.023 0 0 368.957 311.414 363.288 cm
/Im1 Do
Q
BT
/F5 1 Tf
9.845 0 0 9.845 310.8472 344.3527 Tm
[(FIG.)-348.3(2.)-1000.6(\(a\))]TJ
/F4 1 Tf
5.6146 0 TD
[(Time)-318.6(evolution)-315.8(of)-318.7(HIV)-321.3(infection)-317(during)-317.1(zido-)]TJ
-5.6146 -1.0135 TD
[(vudine)-312.5(\(ZDV\))-318.7(monotherapy)-314(is)-312.9(depicted)-317(on)-312.9(the)-315.3(left)-310.7(side.)]TJ
/F5 1 Tf
23.0687 0 TD
(\(b\))Tj
/F4 1 Tf
-23.0687 -1.0135 TD
[(The)-535.1(doses,)-533.2(administrated)-542.1(twice)-538.3(a)-532(day,)-537.3(are)-535.1(computed)-535.6(by)]TJ
T*
[(means)-255.9(of)-249.6(a)-255.5(feedback)-260.2(linearizing)-257(impulsive)-253.5(control;)-257.2(their)-254.1(am-)]TJ
0 -1.0077 TD
[(plitude)-302.3(is)-301.4(drawn)-300.6(on)-295.7(the)-303.8(right)-299(side.)]TJ
/F1 1 Tf
8.9663 0 0 8.9663 59.7543 749.5368 Tm
[(HIV)-301.4(DYNAMICS)-303.1(MODELING)-305(AFTER)-305.7(ANTIRETROVIRAL)-305.3(INITIATION)-21673.9(237)]TJ
ET
endstream
endobj
81 0 obj
<>stream
Adobe d C
s !1AQa"q2B#R3b$r%C4Scs5D'6Tdt&
EFVU(eufv7GWgw8HXhx)9IYiy*:JZjz ? 꿜~ѵ-#AQ]I--5'rڊ;3?ߚG澛?æ^6wp *x:e
ߧ_C͛6s}wZe>Pӵt'TviqwS% S!i C7[?:^ T3 S!i C7[?9 T3 S!i C ]l[K_XVdBA? :|G7W젺KOؑN o8 y HZPN o8 y HZPN .C_0ZY'M[Ϩ|$Kui8cN o8 y HZPNw o8 y HZPN o8 y HZPCý,`sD0}8cN o8 y HZPN o8 y HZPN -4O[D:n{ R>IeeN o8 y HZPN o8 y HZPN o8 y HZP
mcTUV6FzHK S!i C7[?:^ T3 S!i C7[?:^ T3 S!i C_}scۻ-Vԕ% L l|癬m7D4_Rex{_-/?O q -/?O q -?O [u~bGipM6}~2 yKB ot -?f y;B ot -?f yKB ot -?bߗyy~w]Hky,$aPd<